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1. Down Syndrome pathophysiology 
 
Down syndrome (DS) is the most frequent genetic cause of intellectual disability in children and adults. 
The disorder results from the presence of an extra copy of human chromosome 21 (HSA21) or of a major 
portion of this chromosome, and hence is also referred as trisomy 21.  
The pathology was first described in 1866 by the English physician John Langdon Down 1, but it was 
only in 1959 that the French geneticist Jerome Lejeune showed that the syndrome was actually due to 
trisomy of chromosome 21 2,3.  
The onset of DS-related phenotypes occurs during prenatal development, although some of the 
manifestations of the disorder may become apparent only in adulthood 4. 
In DS children, both long and short-term memory are affected. On the other hand, DS children perform 
worse than healthy children in explicit memory tasks, while learning ability in tasks requiring implicit 
memory processing is spared. This could be due to the fact that implicit memory typically relies on 
automatic processes thus requiring low attention levels; on the contrary explicit memory involves 
intentional learning and retrieval strategies, demanding a high degree of attention 5. 
Individuals with DS also display language deficits. Indeed, poor expressive language and impaired 
reading ability, as well as difficulty in the acquisition of new words probably derive from a disturbance of 
the verbal short-term memory system 4. 
The profile of DS cognitive impairment is accompanied by specific neuroanatomical modifications. First, 
brains of adults with DS are about 20% smaller than healthy controls. This phenotype is already present 
during gestation, and it worsens after birth. More specifically, morphological alterations have also been 
detected in DS people at different ages: children and young adults display decreased volume of the 
hippocampus and temporal lobe. Later in life, also other regions such as cerebellum, entorhinal and 
frontal cortex and amygdala appear to be affected 6-9. 
These morphological alterations probably derive from the defective generation of neurons during 
development. Indeed, the hippocampus and neocortex of DS fetuses show reduced number of neurons as 
well as the cortex of DS children. DS cells display a prolonged G2 phase due to the presence of the extra 
chromosome 21, possibly leading to reduced proliferation rate during neurogenesis. In addition, increased 
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apoptosis has also been reported in the hippocampus of DS fetuses. Therefore, brain hypocellularity in DS 
appears to result from both defective neurogenesis and increased apoptosis 10,11 
In older subjects with DS, age-associated degenerative modifications also take place in the brain. Since 
the Alzheimer-related gene APP is triplicated in DS, alterations resembling those typical of Alzheimer's 
disease occur in  almost all DS patients showing extensive Aβ pathology and amyloid plaques deposition 
starting from the age of 30 5,12. 
At the cellular level, neurodevelopmental and degenerative mechanisms contribute to alterations in 
neuronal compartments such as dendrites. Indeed, dendrites in hippocampus and cortex of the adult DS 
brain display decreased length and branching, while also spine density is reduced 13-15. 
In contrast, fetuses and neonates' brains are characterized by a normal or even increased dendritic 
branching 15,16, indicating that degenerative mechanisms take place in older children with DS and progress 
during adulthood with a further reduction of dendritic branching, and length as well as spine density. As 
for dendritic structures, in many cases neuroanatomical and neurochemical alterations arise during 
development and gradually progress over aging. Importantly, since dendritic spines play an essential role 
in network connectivity and brain plasticity, their alterations will probably impact neuronal 
communication and cognitive performance. Moreover, deficits in many neurotransmitter systems 
important for brain development such as GABA (which is the main excitatory neurotransmitter during 
embryonic life), serotonin and dopamine have also been found. Cholinergic system is also affected during 
aging due to the early-onset Alzheimer’s degeneration 5,17.  
2. Pathological mechanisms of Down syndrome 
 
Trisomy 21, is one of the three human trisomies viable in the postnatal period (together with 13 and 18), 
probably due to the small size of chromosome 21 and to the low density of its functional DNA elements. 
The full sequencing of chromosome 21 was achieved in 2000, showing that it contains only 173 protein-
coding genes 18. These genes display broad diversity in their functional properties including kinases, 
genes involved in the ubiquitination pathway, seven ion channels, members of the interferon receptor 
families and, importantly, 18 transcription factors.  Moreover, the chromosome is rich in genes encoding 
for long non-coding RNAs and it also encodes 29 microRNAs 18-20. 
Two main hypotheses have been proposed to explain genotype-phenotype correlation in DS. The first, 
called "gene-dosage effect", states that DS phenotypes results from the dosage imbalance of some 
triplicated dosage-sensitive genes. Supporting this hypothesis, the study of individuals bearing partial 
trisomy 21 allowed the identification of a subset of chromosomes 21 genes whose triplication was 
6    
responsible for most of DS manifestations. Those genes are located on a region spanning about 5.4Mb on 
HSA21q22, called "DS critical region" (DSCR). However, further experiments performed using specific 
mouse strains trisomic for DSCR gene orthologues, showed that DSCR triplication can only explain some 
of the symptoms. This evidence suggested that more complex mechanisms are involved in DS pathology 
21. Moreover, when the trisomic Ts65Dn mouse (which carries the triplication of the distal portion of 
mouse chromosome 16, encompassing genes orthologous to human genes in the DSCR) was crossed with 
mice carrying a deletion of the critical region (returning DSCR gene dosage to normal levels), DS-related 
phenotypes were only attenuated compared to Ts65Dn 22,23. Therefore, at least in animal models, DSCR is 
partially necessary to cause the phenotype, but it is not sufficient to produce all the symptoms of the 
syndrome. Probably, the dosage imbalance of DSCR genes directly contributes to some phenotypes, but 
more complicated mechanisms are needed to explain all DS manifestations 22.  
On the other hand, according to the "Amplified Developmental Instability" hypothesis, a secondary effect 
exerted by the triplicated genes on the whole genome can lead to global gene expression dysregulation. 
This would contribute to at least some aspects of the pathology. For example, triplicated transcription 
factors could regulate the expression of genes located on other chromosomes, leading to a genome-wide 
expression dysregulation 22,24. Indeed, when analyzing mRNA expression in the dorsolateral prefrontal 
cortex and the cerebellar cortex of DS people, Olmos-Serrano et al. found many differentially expressed 
genes localized throughout the genome. Therefore, non-HSA21 genes significantly contribute to DS 
phenotype. Interestingly, less than 50% of those genes were upregulated while the others were 
downregulated, showing that triplication of HSA21 can exert both positive and negative regulation of 
genes located on other chromosomes 25. 
Accordingly, a study on fetal fibroblasts derived from monozygotic twins discordant for trisomy 21, 
identified distinct chromosomal domains composed of adjacent genes sharing the same differential 
expression profile; meaning that regions of upregulated genes follow areas in which genes are 
downregulated 26. 
Interestingly, Olmos Serrano et al. also found that less than 15% of chromosome 21 genes were 
upregulated compared to controls in the prefrontal cortex and the cerebellar cortex of DS people. This 
indicates that regulatory feedback loops may compensate the gene-dosage effect 25.  
Besides, a previous study in lymphoblastoid cell lines had shown that 56% of HSA21 genes were 
expressed at normal levels and that the DS/control ratio was significantly lower than the expected 1.5 for 
many differentially expressed HSA21 genes. This indicates that compensation is mostly due to functional 
negative feedback loops 27. 
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DNA methylation can be one of the mechanisms involved in extensive gene expression alterations as well 
as in mechanisms of compensation. Whole-genome bisulfite sequencing in the frontal cortex of DS 
people highlighted that even if there are no differences in the global methylation level, in DS brains there 
are regions of differential methylation distributed across the entire genome, the majority of these regions 
appeared to be hypermethylated 28. Moreover, Mendioroz et al. showed that increased CpG methylation is 
already present in fetal DS brain and mainly affects developmentally regulated genes. Indeed, differential 
methylation frequently involves sequences containing binding sites for transcription factors that are 
critical for brain development 29. In fact, HSA21 encodes several proteins involved in DNA methylation 
pathways that could mediate these epigenetic changes such as folate pathway enzymes and DNA 
methyltransferases DNMT3L and N6AMT1 28,29. 
 
Chromatin architecture within the nucleus could also be an important factor determining some DS-related 
phenotypes. The assessment of mating performances in three different mouse models (Ts65Dn, Ts1Cje 
and Rb2Cje, which will be described in the next chapter) revealed that the presence of the triplicated 
genes as an extra chromosome in Ts65Dn was impairing normal spermatogenesis and therefore fertility. 
The other two models seem not to be affected, possibly because they are characterized by the 
translocation of the trisomic region rather than the presence of an extra chromosome. Additionally, the 
presence of triplicated genes as an unpaired chromosome lead to global gene expression dysregulation 
that was not detected in the absence of the extra chromosome 30. 
A critical aspect of DS-related mechanisms of gene dysregulation may also involve the spatio-temporal 
dynamics of gene expression. Since the pattern of differentially expressed genes differs between brain 
regions and throughout development, distinct biological processes will be likely affected at different 
stages of brain development and during adulthood 25. For example, sequencing data from DS-derived 
neural progenitor cells (NPCs) and differentiated NPCs, revealed that some pathways (such as focal 
adhesion and extracellular matrix function) are dysregulated at both stages of differentiation while others 
are dysregulated only at specific stages. Interestingly, NPCs dysregulated clusters of genes are mostly 
involved in pluripotency, synapse formation and DNA replication. These functions are of paramount 
importance in the early stages of neurogenesis. Upon differentiation, pathways that were found to be 
affected by trisomy where mainly related to metabolism (glycolysis and gluconeogenesis), axon guidance 
and TGF-beta signaling 31. Moreover, differences were detected in the pattern of dysregulated genes 
found in trisomic fetal brains compared to the adult dorsolateral prefrontal cortex. The two groups of 
samples also differed in the degree of HSA21 gene upregulation. While fetal brains largely adhere to the 
dosage-effect model with a 1.5-fold increase, in adult prefrontal cortex the upregulation was in some 
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cases higher than the expected 1.5-fold, probably due to the emergence of compensatory effects or to 
changes occurring later in life 32. 
 
3. Mouse Models of Down Syndrome 
 
Chromosome 21 encodes approximately 552 genes of which 173 are protein-coding genes, 49 are keratin-
associated proteins (KRTAP; a large family of structural proteins expressed in hair fibers) and 325 are 
non-protein-coding genes. Approximately, 158 orthologous non-KRTAP protein-coding genes are present 
in the mouse genome and are located on three different chromosomes: 102 genes map on the telomeric 
portion of mouse chromosome 16 (Mmu16) spanning about 28Mb; 19 genes map on an internal segment 
of mouse chromosome 17 (Mmu7) of about 3Mb; 37 genes are located on an internal portion of mouse 
chromosome 10 (Mmu10) of about 3Mb 33,34. 
Different mouse models, trisomic for different sets of chromosome 21 genes, have been developed, 
aiming at investigating the many aspects of Down syndrome pathology (Fig.1).  
In 1993, Davisson et al. created the Ts65Dn model, which carries the translocation of a segment of 
Mmu16 on the centromeric region of Mmu17, resulting in a small freely-segregating extra-chromosome. 
The Ts65Dn mouse is currently the only model bearing a genuine aneuploidy. However, in addition to the 
triplication of 92 genes orthologous to HSA21, Ts65Dn mice also carry trisomy of 35 Mmu17 protein-
coding genes that are non-homologous to HSA21. Despite this latter genetic issues, Ts65Dn mice 
recapitulate many of the phenotypic features of the human syndrome and it is currently the only mouse 
model used for preclinical identification of pharmacological interventions targeting DS cognitive 
impairment 4,35,36.  
Additional DS mouse models are trisomic for a subset of genes triplicated in Ts65Dn, but are not 
characterized by an extra freely segregating chromosome. The Ts1Rhr was the first model created using 
Cre-lox technique to carry the triplication of the genes orthologous to DSCR. However, this model failed 
to reproduce all the features of DS phenotype, indicating that in mice the only triplication of this region is 
not sufficient to explain all aspects of the pathology 21. Cre-lox techniques were also used to create mouse 
models bearing tandem duplications of the three complete syntenic regions of HSA21. In particular, the 
Dp(16)1Yey model is trisomic for the entire Mmu16 region syntenic to HSA21, containing 110 
orthologous genes 37, while Dp(17)1Yey and Dp(10)1Yey carry the triplication of Mmu17 and Mmu10 
syntenic regions, respectively 38. Although these models are optimal in terms of genetic triplication, they 
lack the freely-segregating extra chromosome, which is present in Ts65Dn model as well as in the vast 
majority of persons affected by DS 30. 
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In 2005, O'Doherty and colleagues developed the first transchromosomic mouse line (Tc1) which carries 
a freely-segregating copy of the human chromosome 21. Human sequences are expressed both at the level 
of mRNA and protein; however, Tc1 mouse displays mosaicism of the extra-chromosome in several 






In summary, Ts65Dn remains the best-characterized model of DS and also the most widely used since it 
reproduces many phenotypic features of the human pathology. 
 Ts65Dn mice show impaired performances in hippocampal-dependent tasks such as T-maze, contextual 
fear conditioning and novel object recognition. Spatial memory is also reduced in the Morris water maze 
test 35,40-42. In addition, Ts65Dn mice are hyperactive in open field and plus-maze test, in which wild-type 
animals are usually cautious.  
Ts65Dn mice also display neuromorphological alterations typical of DS. For instance, the brain volume 
of Ts65Dn mice is reduced compared to controls during the embryonic period and cell density is 
Figure 1:  Down Syndrome mouse models. Representation of HSA21 and mouse orthologous regions on mouse 
chromosomes 16, 17 and 10. The segment of chromosome triplicated in different mouse models of DS are also 
reported. From: Herault Y., et al., Disease Models and Mechanisms, 2017. 
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decreased during prenatal and early postnatal life in the neocortex. Also, the dentate gyrus of these mice 
has fewer granule cells at all ages 10,43. These alterations are probably due to reduced neural-precursor 
proliferation during embryonic and postnatal development. On the other hand, Ts65Dn mice show a 
larger population of GABAergic neural progenitors in the medial ganglionic eminence, resulting in higher 
numbers of GABAergic interneurons in both hippocampus and cortex later in life 44.  
 
4. GABAergic transmission  
 
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the adult brain through binding 
to both ionotropic (GABAAR) and metabotropic (GABABR) receptors.  
GABABRs are Gi/o-protein-coupled receptors. They are mostly located extra-synaptically and, they can be 
activated by neurotransmitter spilled out from the synaptic cleft thanks to their high affinity for the ligand. 
When coupled with Gαi/o subunits, GABABR activation leads to adenylate cyclase inhibition and to a 
consequent reduction of cAMP levels and PKA activity. When coupled to Gβγi/o subunits, GABABRs 
inhibit voltage-gated calcium channels and activate G protein-coupled inwardly-rectifying potassium 
channels (GIRK). Through these mechanisms, pre-synaptic GABABRs can reduce vesicle release, 
whereas GABABRs located at the spine neck and on the dendrites reduce neuronal excitability 45,46. 
GABAARs are ligand-gated channels permeable to chloride ions and, to a lesser extent, to bicarbonate 
ions. They are composed of five subunits. In the central nervous system, the majority of GABAARs are 
formed by two α, two β and one γ subunits. Many isoforms have been identified for each type of subunit. 
This variability confers different kinetic properties to GABAARs, depending on their composition. For 
instance, receptors bearing α1-3, β2-3 and γ2 subunits are characterized by fast kinetics with rapid onset 
and desensitization, and are frequently located at the synaptic level. On the other hand, the presence of α5 
or δ subunits provides the receptor with high GABA affinity and slow desensitization kinetic; these 
subunits are commonly present outside the synaptic cleft. Notably, extra-synaptic GABAAR containing α5 
and δ subunits are crucial during development when synapses are not entirely formed 47-50 
Upon activation and opening of GABAARs, the direction of the elicited chloride flux depends on the 
intracellular chloride concentration ([Cl-]i) and the related chloride electrochemical gradient. Therefore, 
regulation of chloride homeostasis is essential to obtain a correct excitatory-inhibitory balance, in the 
brain. In neurons, [Cl-]i is regulated by the opposing action of the chloride imported NKCC1 and the 
chloride exporter KCC2 51-53. In particular, if [Cl-]i is low, chloride ions will enter the neuron with a 
hyperpolarizing effect. On the other hand, if [Cl-]i is high, GABAAR opening will elicit a chloride efflux, 
causing a depolarization of the membrane potential. In mature neurons, [Cl-]i is maintained at around  5-7 
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mM and the resulting chloride equilibrium potential is more negative than the membrane resting potential. 
Consequently, chloride currents will have a hyperpolarizing effect (Fig. 2b). In contrast, in developing 
neurons, [Cl-]i is higher (between 15 and 25 mM). Therefore the resulting chloride equilibrium potential is 
less negative than the membrane resting potential in young neurons. This leads to an outward flow of 
chloride associated with a depolarizing effect upon GABAAR opening (Fig. 2a). Importantly, the 
depolarizing effect of GABAergic transmission is considered essential to the development of neuronal 




Since, the membrane resting potential (between -60 and -70 mV) and the chloride reversal potential 
(around -73 mV) are in close proximity, relatively small changes in chloride concentration can trigger a 
shift in GABAergic transmission polarity from hyperpolarizing to depolarizing 57. For this reason, in 
physiological conditions, the action of the two chloride co-transporters KCC2 and NKCC1 tightly 
regulates [Cl-]i to set the reversal potential and the driving force for chloride.  
NKCC1 and KCC2 consist of a 12-segment transmembrane domain, essential for ion translocation, and of 
cytosolic amino- and carboxy-terminal domains required for the regulation of the activity and the 
trafficking of the protein 58. NKCC1 is the main chloride importer that shuttles chloride ions inside the 
Figure 2: Scheme of NKCC1 and KCC2 cotransporters expression and gradients of chloride ions in immature (a) and 
mature (b) neurons. From: Ben-Ari Y., Nat Rev Neurosci.,2002  
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neurons together with K+ and Na+, exploiting the inwardly directed electrochemical gradient of sodium, 
maintained by Na+-K+-ATPase pump. KCC2 is a chloride exporter that extrudes chloride against its 
concentration gradient. This process requires high intracellular potassium levels that are provided by the 
activity of the ATP-dependent pump Na+-K+-ATPase.  The two cotransporters are the main responsible 
for the change in chloride levels occurring during neuronal development and maturation. Indeed, in 
immature neurons, the expression of NKCC1 is higher than KCC2, whose levels are maintained very low. 
During neuronal maturation, KCC2 expression increases dramatically in neurons, leading to progressive 
lowering of [Cl-]i. This phenomenon is termed “GABA developmental switch” and takes place during the 
second postnatal week in rodents and between postconceptional week 40 and 50 in humans 54.  
The GABA developmental shift, and in particular KCC2 upregulation, is essential to allow mature 
neurons to recover rapidly after chloride loading. For this reason, KCC2 expression and activity are 
dynamically regulated in neurons. For instance, Brain-derived Neurotrophic Factor (BDNF) can modulate 
KCC2 levels with opposite effects in immature and mature neurons. In immature neurons, BDNF 
signaling is associated with increased KCC2 mRNA and protein levels mediated by ERK1/2 pathway. 
Moreover, pro-BDNF binding to p75NT receptor inhibits KCC2 expression. Notably, the level of pro-
BDNF is high during development, indicating that KCC2 regulation heavily depends on brain 
development and neuronal maturation 54. Conversely, in adult neurons, BDNF signaling -through TrkB 
receptors- results in a reduction in the levels of both KCC2 mRNA and protein together with diminished 
surface localization.  
Apart from expression itself, another important aspect of [Cl-]i homeostasis depends on the regulation of 
KCC2 activity. Protein kinase C (PKC) phosphorylates KCC2 at Ser940, enhancing the transporter 
activity and its membrane stability 59. KCC2 activity is also regulated by the activation of glutamate 
receptors. Kainate receptor subunit GluK2 can form complexes with KCC2 and PKC. PKC- mediated 
phosphorylation of GluK2 enhances KCC2 activity 60,61. Moreover, PKC can also directly phosphorylate 
KCC2 after being activated downstream of metabotropic glutamate receptors 62. In this framework, an 
increase in excitatory signaling via glutamate transmission can therefore strengthen inhibitory 
transmission through the stimulation of KCC2 activity, thus balancing excitation and inhibition. 
KCC2 activity is also regulated by changes in ionic composition through the lysine deficient protein 
kinase (WNK) pathway and its SPAK/OSR1 (SPS-related proline/alanine-rich kinase or the SPAK 
homolog oxidative stress-responsive kinase 1) effectors. When chloride levels are low, WNK is active 
and can phosphorylate SPAK/OSR1, which in turn phosphorylates KCC2 on threonine or serine residues, 
exerting an inhibitory effect. However, high chloride levels block WNK auto-phosphorylation and 
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activation, thus preventing its inhibitory action on KCC2 activity. Through this mechanism, WNK 
pathway can regulate chloride extrusion rate depending on chloride loading 54,63. Interestingly, the HSA21 
triplicated gene amyloid precursor protein (APP) can also form complexes with KCC2, preventing the 
phosphorylation of some tyrosine residues and inhibiting internalization and degradation of the 
transporter 64. 
While the regulation of KCC2 expression has been extensively studied, less is known about the regulation 
of neuronal NKCC1, except for the observation that seizure induction can upregulate NKCC1 in the brain 
65. However, it is known that WNK-SPAK/OSR1 pathway (that regulates KCC2 activity in response to 
chloride levels) can also regulate NKCC1 activity, by phosphorylating three threonine residues at the N-
terminus of the protein. In this case, WNK activation enhances NKCC1 activity. This mechanism further 
reinforces the importance of this pathway for the regulation of intracellular chloride concentration so that 
low chloride levels will trigger KCC2 inhibition together with NKCC1 activation 54,63.  
Considering its importance for brain development and neuronal communication, it is not surprising that 
dysregulation of chloride homeostasis is a major hallmark of many neurological and psychiatric 
conditions, including chronic pain 66, brain trauma 67-69, autism spectrum disorder 70,71, Down syndrome 
72,73,Rett syndrome 74,75, Fragile X syndrome 71,76, Huntington disease 77, Tuberous sclerosis complex 78, 
22q11.2 microdeletion syndrome 79, maternal immune activation 80 and some forms of epilepsy 81-83.  
 
5. The GABAergic hypothesis for cognitive disabilities in Down syndrome  
 
According to the GABAergic hypothesis for cognitive disabilities in Down syndrome, alterations in 
GABAergic signaling play a critical role in determining DS cognitive impairment by altering the 
physiological excitatory-inhibitory (E/I) balance. Disruption of the optimal E/I balance have been linked 
to  defective synaptic plasticity and memory 72,84,85. A major alteration leading to E/I imbalance is set in 
place during ventral neurogenesis, when the progenitor population in the medial ganglionic eminence 
seems to produce a higher number of interneurons in the Ts65Dn mouse model of DS. This increment is 
probably due to the overexpression of Lhx6, a transcription factor that is essential for neuronal subtype 
specification. This phenotype has been directly linked to the triplication of HSA21 transcription factors 
Olig1 and Olig2 that regulate Lhx6 expression in the medial ganglionic eminence 44. As a result, the 
number of parvalbumin and somatostatin-positive interneurons is increased in the cortex and hippocampal 
CA1 region of Ts65Dn mice 44. Accordingly, pharmacological inhibition of GABAARs rescues both 
hippocampal synaptic plasticity and memory in Ts65Dn mice 84,86,87. 
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Although research on the Ts65Dn model showed an increased number of interneurons, studies on human 
iPSCs-derived neurons have produced conflicting results. Indeed, DS cortical progenitor cells generate a 
smaller number of GABAergic interneurons compared to euploid controls 88. Transcriptome analysis of 
those progenitors highlighted several candidate genes possibly responsible for this phenotype. First of all, 
DLX homeobox transcription factor (which is essential for interneurons generation) is almost absent in 
trisomic NPC. Additionally, the triplication of Olig transcription factors can promote progenitor 
commitment to oligodendrocyte fate at the expense of neuronal fate. In agreement with this hypothesis, 
trisomic NPCs also display increased expression of the oligodendrocyte myelin glycoprotein (OMG) 88. 
Moreover, trisomic GABAergic neurons also show reduced capacity to migrate from MGE while 
differentiated interneurons show impaired ability to project axons to their target. Migration issues are 
probably linked to the triplication of a gene related to the actin cytoskeleton pathway, PAK1, whose 
expression is increased in DS GABAergic interneurons. Accordingly, inhibition of PAK1 partially 
rescues the migration defects 89. 
Hippocampal slices from Ts65Dn mice have been extensively used to assess GABAergic transmission 72. 
In line with the observed increase in the number of GABAergic interneurons, also an increase in 
spontaneous GABAergic postsynaptic events was observed in hippocampal CA1 pyramidal neurons 90. 
However, further functional analysis of GABAergic transmission did not find evidence for changes in the 
frequency of miniature inhibitory postsynaptic currents (mIPSC, which represent activity-independent 
quantal release of GABA) in the same region 90,91. Similarly, no difference was found in the density of 
GABAergic synapses, release probability at GABAergic terminals and evoked GABAA transmission in 
the hippocampal CA1 region of adult Ts65Dn mice 91,92. Therefore, the increased number of GABAergic 
neurons seems not to be directly associated with increased synaptic contacts in the DS brain, indicating 
possible compensatory mechanism limiting GABAergic synapse number. Conversely, mIPSC frequency 
was found decreased (rather than increased) in the hippocampal CA3 region of Ts65Dn mice 93,94. On the 
other hand, mIPSC frequency and evoked GABAergic transmission were found increased in the DG of 
adult Ts65Dn mice, but with this alteration primarily attributed to increased release probability, rather 
than increased synapse number 95,96. These apparently conflicting results may simply indicate possible 
sub-regional differences in the density of GABAergic synapses and its functional consequences. 
Additionally, increased mIPSC frequency and evoked GABAA transmission was only found in the 
hippocampal CA1 of 2 week-old Ts65Dn mice, whereas no difference between trisomic and wild-type 
mice was found in the first and third post-natal weeks. These results also highlight possible age-related 
changes that could nevertheless exert a long-lasting effect on hippocampal network properties, 
contributing to circuit dysfunction later in life 97. 
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Importantly, HSA21 contains the KCNJ6 gene 98,99 which encodes the subunit 2 of the G-protein coupled 
inward rectifier potassium channel (GIRK2). Indeed, both mRNA and protein for GIRK2 are increased in 
the brain of Ts65Dn mice 100,101. In agreement with the fact that GIRK channels are mainly coupled to 
GABABRs in the adult brain 102, GABAB-activated GIRK currents are increased in Ts65Dn cultured 
neurons as well as in CA1 pyramidal neurons and in DG granule cells from acute slices of the Ts65Dn 
hippocampus 92,95,103. This establishes a direct link between DS genetic triplication and GABA signaling. 
Increased GABAB/GIRK signaling alters membrane resting potential and contributes to defective long 
term potentiation (LTP) induction in Ts65Dn mice 95,104. 
Since several studies have proven GABAergic signaling imbalance to be involved in cognitive deficits, 
many studies have assessed the ability of both GABAA and GABAB antagonists to improve cognitive 
performance in DS mouse models. In particular, Fernandez and colleagues tested the efficacy of three 
diverse non-competitive GABAA antagonists: pentylenetetrazole, picrotoxin and bilobalide. They found 
that chronic treatment with these drugs restored LTP and declarative memory in behavioral tasks. 
Interestingly, the beneficial effect was retained up to two months after the suspension of drug 
administration 85. Similar results were found on learning and memory in the Morris water maze after 
chronic pentylenetetrazole (PTZ) treatment 105. Accordingly, picrotoxin treatment also rescued LTP in the 
hippocampal dentate gyrus 96 and CA1 region 84, when administered to slices from Ts65Dn mice. Despite 
their efficacy, it must be considered that GABAA antagonists are burdened by possible pro-epileptic and 
anxiogenic side effects 72,106. However, a more recent study found that the efficacy of PTZ was 
maintained even at a dose 10 times lower, therefore possibly defining a safer therapeutic range 107. Since 
GABAA α5-subunit is highly expressed in the hippocampus, but present only at low levels in other brain 
regions, two different α5-selective antagonists have been tested aiming at reducing the risk of seizure 
induction while promoting cognition. Both compounds were effective in improving cognitive 
performance in DS mice 108-111.  
Although the vast body of evidence points to excess GABAergic signaling in DS circuits dysfunctions, 
some studies have provided evidence of defective GABAA-mediated inhibition 97,104,112,113. In particular, 
Deidda et al. found that GABAAR activation is depolarizing rather than hyperpolarizing in the 
hippocampus and the neocortex of Ts65Dn mice. This action was associated with increased [Cl-]i and a 
more positive value of the chloride reversal potential. Alteration of chloride homeostasis was paralleled 
by an increased expression of the chloride imported NKCC1 in brain samples from both Ts65Dn mice 
and DS people, whereas the expression of the chloride exporter KCC2 was unaffected. Moreover, the 
FDA-approved NKCC1 inhibitor Bumetanide restored chloride reversal potential and rescued memory 
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impairment in Ts65Dn mice 114 (Fig. 3). In view of these results, the rescue of cognitive deficits in 
Ts65Dn obtained with GABAA antagonists could be explained by their ability to reduce aberrant 
(depolarizing) GABAergic signaling 114. As Bumetanide modifies intracellular chloride levels rather than 
acting on GABAAR, its action does not prevent GABA-mediated shunting inhibition106 and will not likely 






6. Biology of microRNAs  
 
Over the last decade, microRNAs (miRNAs) have emerged as critical regulators of the expression and 
function of eukaryotic genomes 115. miRNAs are 21-22 nucleotides (nt) non-coding RNA molecules that 
function as negative regulators of gene expression by interacting mainly (although not exclusively) with 
the 3' untranslated regions (3'UTR) of target mRNAs. The 6-8 nucleotides at the 5' end of the microRNA, 
called seed sequence, primarily mediate the interaction with targets. After binding, miRNAs can either 
mediate mRNA degradation or inhibit its translation, depending on their degree of complementarity 116-118. 
Figure 3: Model of GABAAR-mediated neurotransmission in euploid and Ts65Dn mouse models.   
From: Costa A.C., Nat Med, 2015.  
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Complete sequence complementarity usually leads to target cleavage while partial complementarity, at 
the level of seed binding sequences, promotes translational inhibition 119. 
However, while some works suggest that translational inhibition is the primary mechanism triggered by 
microRNAs 120,121, other studies point to mRNA decay as the main mediator of gene silencing 122,123. In 
some cases, the two mechanisms coexist 124,125 together with mRNA destabilization by deadenylation of 
the poly(A) tail 126 present on the 3’ end of the mRNA. Moreover, according to kinetic studies carried out 
in vitro as well as in vivo in Drosophila, translational inhibition and mRNA decay are probably part of a 
sequential mechanism in which inhibition takes place first and is then is followed by mRNA 
deadenylation and decay to consolidate gene silencing 127-129. 
Transcription of miRNAs is typically performed by the RNA polymerase II. The miRNA primary 
transcripts, named pri-miRNAs, consist of an imperfectly paired stem of about 33 base-pairs, with a 
terminal loop and two flanking segments. Then, two sequential processing reactions trim the pri-miRNA 
transcript into the mature miRNA. The first processing step takes place in the nucleus by the RNA-
binding protein DGCR8 (DiGeorge Critical region) and the RNase III enzyme Drosha, that excises the 
stem-loop from pri-miRNAs to form the pre-miRNA product. In animals, the pre-miRNA is then 
exported to the cytoplasm where the RNase III enzyme Dicer performs the second cleavage reaction. 
Dicer excises the terminal loop from the pre-miRNA stem to produce a mature miRNA duplex of 
approximately 22 base-pair length 115. The mature miRNA duplex associates with Argonaute (Ago) 
proteins in the RNA-induced silencing complex (RISC), where one miRNA strand of the duplex is 
retained while the other is discarded and degraded. To exert gene silencing, miRNA-associated Ago2 
recruits the SDE3 helicase Mov10 130,131, and components of the GW182 family of Trinucleotide repeat-
containing-proteins (a group of genes that is composed of three paralogs in mammals: Tnrc6A, Tnrc6B 
and Tnrc6C). Thanks to the presence of tryptophan repeats, Tnrc proteins can bind several silencing 
effectors such as PolyA Binding proteins (PABP) and deadenylase complexes and are therefore essential 
for miRNA functioning 129,132,133, including translation repression of complimentary mRNA 134 (Fig. 4). 
Thus, miRNAs bound to Ago and Tnrc proteins can be considered the core components of the RISC 
complex, since impairing Ago2-Tnrc interaction prevents miR mediated gene-silencing both in vitro and 
in vivo 135. 





Several studies indicate that miRNAs play critical regulatory roles in different biological processes such 
as neurite outgrowth and synaptogenesis. Interestingly, the production of mature miRNAs from their 
precursors can take place at the synaptic level, where they can regulate synaptic functions without 
requiring changes in mRNA expression 136. Processing of miRNA, can also be triggered by neuronal 
activity. In particular, stimulation of individual synapse can lead to local pre-miR181a processing in the 
dendritic shaft close to the stimulated synapse, allowing a local reduction in target protein synthesis 137. 
For this reason, miRNAs represent an essential layer of regulation to fine-tune expression profiles of 
genes necessary for activity-dependent synaptic plasticity. Accordingly, miRNAs have been recognized 
as key players in the formation and retrieval of memory and contribute to the structural plasticity of 
dendritic spines associated with LTP and LTD 138,139. 
7. microRNAs in development and developmental disorders 
 
miRNAs are essential regulators of the transcriptional network of the developing human brain and are 
probably involved in the onset of neurodevelopmental disorders. Indeed, many miRNAs are differentially 
expressed across different developmental periods (infancy, early childhood, late childhood and 
Figure 4: Overview of the miRNA processing pathway, from synthesis to target translational inhibition 
From: Thomas K.T., et al., Front.Mol.Neurosci. 2018 
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adolescence). Moreover, differential expression of miRNAs between brain regions increases over 
developmental time, suggesting a role for miRNAs in regional specialization during brain maturation. 
Furthermore, putative gene targets of the differentially expressed miRNAs are involved in biological 
processes related to transcriptional regulation, neurodevelopment and neurodevelopmental disorders 140.  
Profiling studies on the rat cortex during development have highlighted that sets of microRNAs share the 
same dynamic of expression throughout development. Some are continuously expressed across all 
developmental phases (for instance miR9 and let7), while others are selectively expressed over a short 
period. The second group might be involved in specific processes taking place during cortical 
development such as proliferation, differentiation, migration and network formation 141.  Indeed, 
microRNA-depleted neural stem cells can self-renew for several days in vitro, but they are not able to 
differentiate. This suggests that microRNA depletion (mediated by Dicer deletion) mostly affects cell-fate 
transition and maturation toward a more restricted progenitor cell type 142. Considering that the extent of 
expression regulation exerted by a single microRNAs is relatively mild, it is likely that groups of co-
expressed microRNAs cooperate to achieve the fine-tuned control required for the precise coordination of 
phase transition. On the other hand, a single microRNA can efficiently regulate a specific function by 
targeting several genes involved in the same pathway or exerting redundant functions 141. 
MicroRNAs have been proven essential also for the control of physiological plasticity in adult neurons. In 
general, synaptic suppression seems to be one of the prominent functions of microRNAs at the synaptic 
level. For instance, miR138 can regulate the palmitoylation status of several proteins functioning at the 
synapse 143, while miR375 can downregulate BDNF to inhibit dendritic growth 144. However, evidence of 
positive regulation of target gene expression at the synaptic levels have also been reported. For instance, 
miR124 enhances long-term facilitation by de-repressing the activity-dependent transcription factor 
CREB 145. 
MicroRNAs can control synaptic transmission at multiple steps: from neurotransmitter synthesis to signal 
termination. Indeed, microRNAs regulate expression of various neurotransmitter receptors (including 
glutamate and GABA receptors) 146-149 as well as neurotransmitter release by targeting components of the 
SNARE complex or proteins regulating pre-synaptic calcium levels 150-152. Neurotransmitter reuptake is 
another step of neuronal signaling that can be regulated by microRNAs. For example, miR16 can increase 
the efficacy of serotonin signaling by downregulation of the serotonin transporter SERT 153. 
Consistent with the fact that microRNAs action affects gene expression in every stage of 
neurodevelopment, their dysregulation is involved in the onset of several neurodevelopmental disorders, 
including autism 154,155, epilepsy 156 and Fragile X syndrome 157. Moreover, several miRNAs have been 
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found dysregulated in DS and Ts65Dn samples. However, among the 29 microRNAs encoded on 
chromosome 21, only a 5 (miR99a, let7c, miR125b-2, miR155 and miR802) have been detected at the 
expected ratio of 1.5 in DS compared to controls 158. Nevetheless, since single microRNAs can regulate 
multiple target RNAs, these five miRNAs could potentially regulate the expression of more than 3600 
genes, playing an important role in the developmental and functional defects as well as in the phenotypic 
variation observed in people with DS 158,159. Among the many, Methyl-CpG-binding protein transcription 
factor 2 (MeCP2) is one of the most interesting targets of HSA21-triplicated miRNAs. Indeed, MeCP2 is 
involved in many brain functions including neurogenesis and spine formations, and its mutation leads to 
Rett syndrome 160,161. The 3’UTR of MeCP2 harbors two binding sequences for miR155 and miR802 in 
addition to a single seed-binding sequence for miR125b and let-7c. Indeed, its levels were found 
decreased in trisomic samples from humans and Ts65Dn mice 162.  
In agreement with the Amplified Developmental Instability hypothesis, several studies found that also 
other microRNAs, lying outside chromosome 21, are dysregulated in Ts65Dn and DS samples compared 
to controls. A study in the cerebrum of adult Ts65Dn mice found 20 microRNAs (including miR195 and 
miR497) whose expression was decreased in Ts65Dn brains. Interestingly, these down-regulated 
microRNAs were disomic. On the other hand, among the trisomic microRNAs, only miR-155 displayed a 
1.8 fold increase, whereas no differences were detected in the expression levels of the other four 
microRNAs 163. Accordingly, a study focusing on the lymphocytes from children with trisomy 21 found 
that not all the triplicated microRNAs were up-regulated at ratios higher than 1.5, whereas 114 
microRNAs encoded outside chromosome 21 were differentially expressed 164. Lin et al. characterized the 
expression profile of both microRNAs and protein in fetal cord blood samples, aiming to understand the 
functions of dysregulated microRNAs that are important for embryonic development. They found 344 
differentially expressed microRNAs (including miR101, miR16 and miR195) and 505 differentially 
expressed proteins 165. Another study carried out a correlation analysis of microRNAs and gene 
expression profiles in fetal hippocampal tissues to identify a network dysregulation that could cause 
cognitive impairment in DS. They found a total of 995 pairs of altered microRNAs and predicted targets 
whose functional analysis revealed a prominent role in the regulation of transcription 166. Moreover, a 
study comparing the transcriptome of Ts65Dn and WT hippocampi found eleven differentially expressed 
microRNAs. Among these, six were up-regulated (miR-210, miR155, miR214, miR138, miR423-5p and 
mi223) while five were down-regulated (miR7b, miR181c, miR369-5p, miR361 and miR135b). Notably, 
the down-regulated miR7b targets the Fos gene, an important regulator of cell signaling and synaptic 
plasticity 167. 
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Many other neurological disorders are associated with altered gene expression regulation by miRNAs 168. 
MicroRNAs are differentially expressed during all phases of epileptogenesis both in humans and in 
animal models of the pathology. In this context, microRNAs targeting ion channels are crucial. Indeed, 
ion channels can modulate intrinsic neuronal excitability. For instance, miR33, which is down-regulated 
in animal models of epilepsy, targets two GABAAR subunits (α4 and β2) as well as KCC2 transporter, 
indicating an essential role of miR33 in regulating inhibitory signaling in the brain 156. 
Several single nucleotide polymorphisms (SNP) in the gene encoding for miR137 are associated with an 
increased risk of schizophrenia. In particular, alleles linked to elevated risk of schizophrenia are 
associated with low miR137 levels. Conversely other SNPs, associated with higher miR137 levels, are 
considered protective 169,170. Moreover, also miR195-5p levels have been found reduced in patients with 
schizophrenia 171. 
Fragile-X syndrome is also linked to microRNA pathway dysfunction. Indeed, the fragile X mental 
retardation protein (FMRP) participates in pri-miRNA processing by up-regulating Drosha at the 
translational level. Consequently, FMRP dysfunction results in the accumulation of pri-miRNAs and the 
reduction of pre-miRNA levels 157. Moreover, FMRP regulates diverse mechanisms in cooperation with 
specific microRNAs. For example, FMRP phosphorylation promotes miR125a association with AGO2 
complex, and the interaction with PSD95 mRNA. Moreover, miR181d and FMRP cooperatively repress 
the translation of the proteins involved in axon elongation process (Map1 and Calm1). On the other hand, 
FMRP mRNA is targeted by microRNAs such as miR130b whose levels negatively correlates with 
FMRP protein in mouse embryonic neural precursor cells as well as in humans 172. 
Concerning autism spectrum disorders (ASD), the identification of specific genetic variants unequivocally 
leading to the pathology has not been achieved yet. However, microdeletions and microduplications 
(collectively referred as copy number variations; CNVs) at multiple chromosomal loci seem to be 
implicated in the disorder. Aiming to explain the genetic heterogeneity underlying ASD, a study 
investigated the involvement of microRNAs encoded in CNVs and identified ten microRNAs (including 
miR195 and miR497) as hub molecules. Many of these hub microRNAs formed regulatory loop with 
transcription factors and their downstream targets were involved in neurodevelopment and synapse 
formation 154. 
8. Aim of the project 
 
Deidda et al. found that NKCC1 chloride importer is upregulated both in Ts65Dn mice and in DS human 
samples 114, suggesting that modulation of NKCC1 expression could be a promising strategy to improve 
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cognition in DS. Since NKCC1 gene (Slc12a2) is not located on chromosome 21, and consequently it is 
not triplicated, the project aims to address the molecular mechanisms responsible for NKCC1 regulation 
in DS brains. In this case, it is also essential to understand the relation linking trisomy of chromosome 21 
to NKCC1 upregulation. 
Even though NKCC1 protein expression is highly dynamic during development and its changes have 
been extensively studied, the molecular mechanisms underlying NKCC1 developmental changes are 
currently unknown. Therefore, this study could also shed light on physiological regulation of NKCC1. 
Moreover, dysregulation of chloride homeostasis is a major hallmark of many neurological and 
psychiatric conditions, including epilepsy, traumatic brain injury, ischemia, tuberous sclerosis, Rett 
syndrome, Fragile X, autism and chronic pain. Therefore, treatment of these pathologies could as well 
benefit from this study and the possibility to regulate NKCC1 levels by interfering with the molecular 
mechanisms underlying NKCC1 expression in physiology and/or pathology. 
We hypothesize that understanding the mechanisms leading to NKCC1 differential expression in Ts65Dn 
neurons will allow us to manipulate its levels to restore physiological chloride concentration and possibly 
rescue cognitive impairment in Ts65Dn mice.  
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MATERIALS AND METHODS 
 
1. Cloning and plasmid construction 
 
The   ̴ 2.8 Kb mouse NKCC1 3’UTR was PCR-amplified from the genomic BAC clone RP24-109M9 
(BACPAC Resources) and cloned in psiCHECK2 plasmid (Promega) downstream of Renilla luciferase 
(Rluc) coding sequence. This plasmid also expressed Firefly luciferase (Fluc) from a second promoter 
that serves as internal control. With this system, changes in the Rluc/Fluc ratio will reflect the degree of 
NKCC1 3’UTR post-transcriptional regulation. 
To assess the repression activity of NKCC1 3’UTR specifically in neuron, we constructed a sensor 
plasmid (termed biSyn-EGFP-TOM) in which two identical expression cassettes bearing the neuro-
specific human Synapsin promoters (hSyn) drive the expression of EGFP or tdTomato fluorescent 
proteins. NKCC1 3’UTR was sub-cloned downstream of EGFP sequence. Therefore, the EGFP/tdTomato 
ratio reflects changes in post-transcriptional regulation exerted by NKCC1 3’UTR. Mutations of 
miR497a-5p and miR101-3p seed-binding sequences on NKCC1 3’UTR was performed by standard PCR 
techniques. 
 
2. Real-Time Quantitative PCR (RT-qPCR)  
 
RT-qPCR was performed as previously described 73,173. Total RNA was extracted with QIAzol reagent 
and purified on miRNeasy spin columns (Qiagen), which includes an in-column RNAse-free DNAse 
digestion for the removal of contaminating genomic DNA. RNA samples were quantified at 260 nm with 
a ND1000 Nanodrop spectrophotometer (Thermo Scientific). RNA purity was also determined by 
absorbance at 280 and 230 nm.  
For mRNA analysis, reverse transcription was performed according to the manufacturer’s 
recommendations on 1 µg of RNA with QuantiTect Reverse Transcription Kit (Qiagen). SYBR green RT-
qPCR was performed in triplicate with 10 ng of template cDNA using QuantiTect master mix (Qiagen) on 
a 7900-HT Fast Real-time System (Applied Biosystem), using the following universal conditions: 5 min 
at 95 °C, 40 cycles of denaturation at 95 °C for 15 sec, and annealing/extension at 60 °C for 30 sec. 
Product specificity and occurrence of primer dimers were verified by melting curve analysis. Primers for 
mRNA detection (see table 1) were designed with Beacon Designer software (Premier Biosoft) in order to 
avoid template secondary structure and significant cross homologies regions with other genes by BLAST 
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search. For each target gene, primers were designed to target specific transcript variants annotated in 
RefSeq database (http://www.ncbi.nlm.nih.gov/refseq).  
For miRNA analysis, we adopted the previously described poly(A) tailing method 174. In brief, 2.5 µg of 
total RNA were first poly-adenylated with Poly(A) Polymerase (Ambion) and 0.2 µM ATP for 15 min at 
37°C. Four-hundred ng of poly(A) tailed RNA were then reverse-transcribed with SuperScript™ III First-
Strand Synthesis SuperMix (Invitrogen) and 3.75 µM of a PolyT anchor oligo (5′-
GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTTTTTTTTVN-3′) for 50 min at 
50°C. SYBR green RT-qPCR for microRNA was performed in triplicate with 4 ng of template cDNA (as 
above) with a miRNA-specific forward primer (see table 2) and a universal adaptor reverse primer (5′-
GCGAGCACAGAATTAATACGAC-3′). 
In each experiment, no-template controls (NTC) and RT-minus controls were run in parallel to the 
experimental samples. PCR reaction efficiency for each primer pair was calculated by the standard curve 
method with serial dilution of cDNA. PCR efficiency calculated for each primer set was used for 
subsequent analysis. All experimental samples were detected within the linear range of the assay. Gene 
expression data were normalized by the multiple internal control gene method 175. 
To determine an accurate normalization factor for data analysis the expression stability of different 
control genes was evaluated with GeNorm algorithm 175 available in qBasePlus software (Biogazelle). 
The tested control genes for mRNA analysis were: Gapdh (glyceraldehyde-3-phosphate dehydrogenase), 
Ppia (peptidylprolyl isomerase A) and Actb (β-actin). Normalization of miRNA expression data was 
similarly performed with small nucleolar RNAs (snoRNA) snord65, snord70, snord110 and U6 Small 
nuclear RNA (snRNA). Based on the relative expression stability of the control genes calculated by 
GeNorm analysis, expression data for mRNA analysis were normalized with Gapdh and Ppia, while 
expression data for miRNA analysis were normalized with snord70 and snord110. Calibration curves 







Forward primer Reverse primer 
Actb NM_007393 AAGTGGTTACAGGAAGTCC ATAATTTACACAGAAGCAATGC 
Gapdh NM_008084 GAACATCATCCCTGCATCCA CCAGTGAGCTTCCCGTTCA 
Ppia NM_008907 CACTGTCGCTTTTCGCCGCTTG TTTCTGCTGTCTTTGGAACTTTGTCTGC 
Nkcc1 
(Slc12A2) 
NM_009194 GCTCTATCTAAGGACCTACCACCA AGGCACTGAAGTACCATTCTGGAG 
TNRC6c NM_198022 CTCGTGGTCTCTGTCTTG AATAACATCTTCAGTGCTAGGA 
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Gene name Accession Number Forward primer 
mmu-Sno65 NR_028541 TTACCGGCAGATTGGTAGTG 
mmu-Sno70 NR_028554 ACAAAAATTCGTCACTACCACTG 
mmu-Sno110 NR_003078 AGATCACTGACGACTCCATGTG 
mmu-miR101-3p NR_029537 CGCAGTACAGTACTGTGATAACTGAA 
mmu-miR15a-5p NR_029733 TAGCAGCACATAATGGTTTGTGAA 
mmu-miR15b-5p NR_029529 TAGCAGCACATCATGGTTTACAAA 
mmu-miR16-5p NR_029734 TAGCAGCACGTAAATATTGGCG 
mmu-miR195-5p NR_029581 TAGCAGCACAGAAATATTGGCAA 
mmu-miR322-5p NR_029756 AGCAGCAATTCATGTTTTGGA 
mmu-miR497a-5p NR_030444 CAGCAGCACACTGTGGTTTGTA 
hsa-Sno65 NR_003054 ACCGGCAGATTGTGTAGTGG 
hsa-Sno70 NR_003058 TTCGTCACTACCACTGAGACAAC 
hsa-Sno110 NR_003078 ATCTGTCAATCCCCTGAGTGC 
hsa-miR101-3p NR_029836 CGCAGTACAGTACTGTGATAACTGAA 
hsa-miR15a-5p NR_029485 TAGCAGCACATAATGGTTTGTGAA 
hsa-miR15b-5p NR_029663 TAGCAGCACATCATGGTTTACAAA 
hsa-miR16-5p NR_029486 TAGCAGCACGTAAATATTGGCG 
hsa-miR195-5p NR_029712 TAGCAGCACAGAAATATTGGCAA 
hsa-miR424-5p NR_029946 CAGCAGCAATTCATGTTTTGAA 

















Actb mouse NM_007393 123 0.1 -3.130/0.986 108.7 
Gapdh mouse NM_008084 77 0.2 -3.370/0.999 98.0 
Pppia mouse NM_008907 133 0.2 -3.321/0.994 100.0 
Nkcc1 (Slc12A2) mouse NM_009194 101 0.2 -3.280/0.999 101.8 
Tnrc6c mouse NM_198022 118 0.2 -3.306/0.999 96.6 
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mmu-Sno65 mouse NR_028541 0.2 -3.383/0.999 97.5 
mmu-Sno70 mouse NR_028554 0.2 -3.342/0.999 99.2 
mmu-Sno110 mouse NR_003078 0.2 -3.459/0.999 94.6 
U6 mouse NR_003027 0.2 -3.411/0.997 96.4 
mmu-miR101-3p mouse NR_029537 0.2 -3.432/0.999 95.6 
mmu-miR15a-5p mouse NR_029733 0.2 -3.262/0.999 102.6 
mmu-miR15b-5p mouse NR_029529 0.2 -3.349/0.999 98.9 
mmu-miR16-5p mouse NR_029734 0.2 -3.259/0.997 101.1 
mmu-miR195-5p mouse NR_029581 0.2 -3.437/0.997 95.4 
mmu-miR322-5p mouse NR_029756 0.2 .3.343/0.992 99.1 
mmu-miR497a-5p mouse NR_030444 0.2 -3.336/0.986 99.4 
hsa-Sno65 human NR_003054 0.2 -3.283/0.996 101.6 
hsa-Sno70 human NR_003058 0.2 -3.23/0.999 103.9 
hsa-Sno110 human NR_003078 0.2 -3.514/0.928 92.56 
U6 human NR_004394 0.2 -3.346/0.998 99.01 
hsa-miR101-3p human NR_029836 0.2 -3.432/0.999 95.6 
hsa-miR15a-5p human NR_029485 0.2 -3.262/0.999 102.6 
hsa-miR15b-5p human NR_029663 0.2 -3.349/0.999 98.9 
hsa-miR16-5p human NR_029486 0.2 -3.259/0.997 101.1 
hsa-miR195-5p human NR_029712 0.2 -3.437/0.997 95.4 
hsa-miR424-5p human NR_029946 0.2 -3.426/0.934 95.8 
hsa-miR497a-5p human NR_030178 0.2 -3.336/0.986 99.4 
 
3. Human Brain Samples 
 
Hippocampal samples from adult human Down syndrome patients and age/sex-matched non-trisomic 
controls were obtained from the Brain and Tissue Bank for Developmental Disorders at the University of 
Maryland, Baltimore (MD). Samples information are described in Table 4 and were previously reported 
73. 
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TABLE 4 
Case number Disorder Age (years) Gender 
1276 DS 13 M 
5277 DS 19 M 
5341 DS 25 M 
5005 DS 39 F 
M1960M DS 19 M 
4925 Control 13 M 
1841 Control 19 M 
605 Control 25 M 
5606 Control 35 F 
4782 Control 18 M 
 
 
4. Primary cultures and transfection 
 
Primary neuronal cultures were prepared from WT and Ts65Dn pups at postnatal day 2 (P2), as 
previously described 176,177. In brief, brains were dissected under a stereomicroscope in ice-cold 
Dissection Buffer (DB) composed of Hank’s Balanced Salt Solution (HBSS; Gibco) supplemented with 6 
mg/mL glucose, 3 mg/mL bovine serum albumin (BSA), 5.5 mM MgSO4, 5 µg/mL gentamycin and 10 
mM Hepes, pH 7.4 (all from Sigma). Cortical or hippocampal tissue was minced and then enzymatically 
digested with 0.25% trypsin in HBSS (Gibco) containing 0.6 mg/mL Deoxyribonuclease I (DNAse; 
Sigma) for 5 min at 37°C. Tissue chunks were washed in DB, incubated for 5 min in DB supplemented 
with 1 mg/mL of Soybean trypsin inhibitor (Sigma) and mechanically dissociated in DB supplemented 
with 0.6 mg/mL DNAse. Cells were passed through a 40 µm cell strainer and then centrifuged (110 x g 
for 7 min at 4°C) to remove cellular debris. Cells were plated on glass coverslips, 6-wells plates or MEA 
coated with poly-L-lysine (Sigma; 0.1 mg/mL in 100 mM borate buffer, pH 8.5) at a density of 250-500 
cells/mm2. Neurons were maintained in a culture medium consisting of Neurobasal-A supplemented with 
2% B27, 1% GlutaMax and 5 µg/mL gentamycin (all from Gibco) at 37 °C in humidified atmosphere 
(95% air, 5% CO2).  
Primary cortical glial cultures were prepared from WT and Ts65Dn pups at P4. In brief, brains were 
dissected under a stereomicroscope in ice-cold HBSS. Cortical tissue was minced and then enzymatically 
digested with 0.25% trypsin in HBSS containing 1 mg/mL DNAse for 15 min at 37°C. Tissue chunks 
were washed in Glial medium (MEM supplemented with 10% horse serum, 1% Pen-Strep, 33 mM 
glucose and 1% glutamine, all from Gibco) and then centrifuged for 5 minutes at 1200 rpm. Pellet was 
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resuspended in fresh glial medium and mechanically dissociated. Cells were passed through a 40 µm cell 
strainer and plated on petri dishes coated with poly-D-lysine (Sigma; 0.01 mg/mL in H2O). A complete 
medium change was performed the next day. Cells were maintained at 37 °C in humidified atmosphere 
(95% air, 5% CO2) with half-medium change every week. Cells were harvested at 14-16 DIV. 
microRNA mimics and inhibitors were purchased from Ambion (Thermo Fisher Scientific). For 
biochemistry experiments, neurons were plated in 6-wells plates and transfected at 6 DIV with 45 pmol 
(30 nM final concentration in well) of microRNA mimics (mirVana Control mimic, catalog number: 
4464058; mirVana m497a-5p mimic, ID: MC11293; mirVana m101a-3p mimic, ID: MC11414) or 
microRNA inhibitors (mirVana Control inhibitor, catalog number: 4464076; mirVana m497a-5p 
inhibitor,: MH11293; mirVana miR101a-3p inhibitor, ID: MH11414). Cells were harvested two days 
after transfection. For MEA recording and MQAE imaging experiments, neurons were transfected at 13 
DIV with 6.5 or 25 pmol of microRNA mimics, respectively (10 nM final concentration in wells for 
both). Chloride imaging and MEA recordings were performed three days after transfection. For 
simultaneous transfection experiments with two microRNA mimics, neurons were transfected with a 1:1 
mixture of each microRNA mimic (thus maintain the unaltered total amount of transfected mimics). 
The specific short interfering RNA (siRNA) against Tnrc6c (Silencer Select Tnrc6c siRNA, ID #s103983) 
and control siRNA (Silencer Select Control siRNA, catalog number: 4390843) were also purchased from 
Ambion. Neurons plated in 6-wells plates were transfected at 5 DIV with 25 pmol (16.7 nM final 
concentration in wells) of siRNA. Transfected neurons were lysed four days after transfection. All RNA 
transfections were performed with 0.1 µl/pmol RNA of Lipofectamine RNAiMAX (Thermo Fisher 
Scientific).  
For imaging experiments with biSyn-EGFP-TOM sensor, neurons were co-transfected at 13 DIV with 0.5 
µg of plasmid and 12.5 pmol (4.8 nM final concentration in well) of microRNA mimics with 0.5 µl 
Lipofectamine2000 (Thermo Fisher Scientific) following manufacturer’s instructions. Neurons were fixed 
with 4% paraformaldehyde 2 days after transfection for subsequent image analysis.  
For dual-luciferase assay, cortical neurons were plated in 24 well plates. Neurons were transfected at 7 
DIV with 0.2 µg of psiCHECK-2-NKCC1-3’UTR plasmid and 0.2 µL of Lipofectamine2000. Dual-
luciferase measurements were performed at 15 DIV. 
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5. RNA interference 
Sequences used for RNA interferences (RNAi) experiments were selected with BLOCK-iT RNAi 
Designer (Invitrogen). For viral expression of artificial microRNAs (amiRs) against mouse NKCC1 
(SLC12A2: NM_009194) two amiR sequences (NKCC1 amiR #1: TTAACATGCAGCGGACTAATA 
and NKCC1 amiR #2: ATCACCAGCAGCACAATCTGA) were first cloned into the pcDNA6.2-
GW/EmGFP-miR plasmid using the BLOCK-iT Pol II miR RNAi kit (Invitrogen), as previously 
described 178,179. The expression cassette thus consisted of a 5' miR flanking region, a target-specific stem-
loop amiR sequence and a 3' miR flanking region. This amiR cassette can be expressed from the 3’ 
Untranslated Region (UTR) of any reporter gene under the control of a RNA polymerase type II promoter 
180. As a negative control, we used the control amiR sequence from pcDNA6.2-GW/EmGFP-miR-neg-
control plasmid (provided with the kit) containing a sequence that did not target any known vertebrate 
gene (Control amiR: AAATGTACTGCGCGTGGAGAC). The amiR expression cassettes were then sub-
cloned in lentiviral vector (LV) plasmids derived from pCCL.sin.cPPT.PGK.GFP.WPRE 181 (kind gift by 
L. Naldini, TIGET, San Raffaele Scientific Institute, Milan, Italy) downstream of the green fluorescent 
protein EGFP under the control of the human phosphoglycerate kinase promoter (hPGK) or downstream 
of the red fluorescent protein mCherry under the control of the neuro-specific human synapsin promoter 
(hSyn). 
For viral expression of the short interference RNA (shRNA) against APP, a pair of DNA oligos (listed in 
table 5) were in vitro annealed and cloned downstream of the human U6 Pol III promoter in the pRNAT-
U6 plasmid (GenScript). The U6 expression cassette was then sub-cloned in the AAV-hSyn-tdTomato 
vector (an adeno-associated virus vector plasmid derived from pAAV-hSyn-EGFP; Addgene #50465). 
 
TABLE 5 










For viral expression of microRNA mimics we adopted a previously described strategy that minimizes 
passenger-strand-mediated off-target effects 182. For each microRNA mimic, a pair of DNA oligos (listed 
in table 6) were in vitro annealed and cloned downstream of the human U6 Pol III promoter in the 
pRNAT-U6 plasmid (GenScript). The U6 expression cassettes were then sub-cloned in the AAV-hSyn-
tdTomato vector.    
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TABLE 6 














6. Viral preparations 
 
VSVG-pseudotyped third-generation LVs were produced by transient co-transfection into HEK293T cells 
using the calcium phosphate transfection method. Supernatants were collected, passed through a 0.45 μm 
filter and purified by ultracentrifugation, as previously described 178,181. LVs were titrated at 
concentrations ranging from 5.0 x 108 to 1.0 x 109 transducing units (TU)/mL by FACS analysis on 
HEK293T or Neuro2a cells by the limiting dilution method. Neuronal cultures were infected with 
lentiviruses at 7 DIV by using 5-10 multiplicity of infection (MOI) and used for experiments between 15 
and 20 DIV. The efficiency of infection was estimated to range between 80 and 95% of cells.  
AAV chimeric serotype 1/2 (AAV1/2) vectors were produced using a slight modification of the 
adenovirus-free transient transfection methods described before 183,184. Briefly, adherent HEK293 cells 
were transfected with three plasmids containing the adenovirus helper proteins, the AAV Rep and Cap 
genes, and the ITR-flanked transgene expression cassette. Three days after transfection, cells were 
harvested, lysed and treated with benzonase (Sigma). AAV1/2 vectors were purified by affinity columns as 
previously described 185. The final AAV products were formulated in sterile phosphate buffered saline 
containing 0.001% of pluronic F-68 (Sigma), and stored at -80°C. AAV vector were titrated at 
concentrations ranging from 1.8 x 1011 and 1.0 x 1012 viral genome (vg)/mL by qPCR assay. Neuronal 
cultures were infected with AAV vectors at 7 DIV with 1.2 x 108 vg for miR mimics and 1.0 x 109 vg for 
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7. Biochemistry 
 
Samples were lysed in ice-cold RIPA buffer (1% NP40, 0.5% Deoxycholic acid, 0.1% SDS, 150 mM 
NaCl, 1 mM EDTA, 50 mM Tris, pH 7.4) containing 1 mM PMSF, 10 mM NaF, 2 mM sodium 
orthovanadate and 1% (v/v) protease and phosphatase inhibitor cocktails (Sigma). Samples were clarified 
through centrifugation at 20,000 x g at 4°C, and the protein concentration was determined using the BCA 
kit (Pierce). For immunoblot analysis, protein extracts were prepared in lithium-dodecyl-sulfate (LDS) 
sample buffer (ThermoFisher Scientific) containing 50 mM dithiothreitol (DTT). To avoid NKCC1 
protein aggregation/precipitation, samples were not heat-treated before loading 186,187. Equal amounts of 
proteins were run on 4-12% Bis-Tris, NuPAGE (ThermoFisher Scientific) or Criterion-XT (Bio-Rad) gels 
with MOPS buffer and transferred overnight at 4°C onto nitrocellulose membranes (GE Healthcare) with 
Tris-Glycine transfer buffer (25 mM Tris-base, 192 mM glycine, 20% methanol). Membranes were 
probed with mouse anti-NKCC1 (clone T4c, Developmental Studies Hybridoma Bank; 1:4,000), mouse 
anti-APP (clone 22C11 Sigma catalog no MAB348 1:4,000), chicken anti-GAPDH (Sigma, catalog no 
AB2302, 1:16,000) and rabbit anti-Actin (Sigma, catalog no: A2066; 1:10,000), followed by HRP-
conjugated goat secondary antibodies (ThermoFisher Scientific; 1:5,000). Chemiluminescent signals were 
revealed with SuperSignal West Pico substrate (Pierce) and digitally acquired on a LAS 4000 Mini 
imaging system (GE Healthcare). Band intensities were quantified using ImageQuant software (GE 
Healthcare). The specificity of the anti-NKCC1 antibody was previously verified on brain samples from 
NKCC1 deficient mice 73. 
 
8. MQAE intracellular chloride imaging 
 
Imaging of intracellular Cl- in hippocampal neurons was performed with the fluorescent chloride-sensitive 
indicator MQAE [N-(Ethoxycarbonylmethyl)-6-Methoxyquinolinium-Bromide], as previously described 
73. MQAE dye detects Cl- ions via diffusion-limited collisional quenching, resulting in a concentration-
dependent decrease of fluorescence emission following an increase in Cl- concentration 188. Therefore, a 
decrease in MQAE fluorescence is indicative of a higher [Cl-]i and vice versa. Hippocampal neurons at 15 
DIV were loaded with 5 mM MQAE (Molecular Probes) for 30 minutes at 37°C. Coverslips were then 
transferred to a holding chamber and perfused (2 mL/min) with extracellular solution (NaCl 145 mM, 
KCl 5 mM, CaCl2 2 mM, MgCl2 1 mM, HEPES 10 mM, D-glucose 5.5 mM, pH 7.4) at 25°C for 5 
minutes before imaging. Images were taken with a Nikon A1 scanning confocal microscope equipped 
with a 20X air-objective (NA 0.75). MQAE was excited with a 405 nm diode laser and fluorescence 
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collected with a 525/50 nm band-pass emission filter. All excitation and acquisition parameters (laser 
intensity, PMT offset and gain) were keep constant throughout experiments. Image analysis was 
performed with NIS-Elements software (Nikon) by measuring the mean fluorescent intensity of regions of 
interest (ROIs) covering on the cell body of individual neurons from 6 randomly-selected fields of view 
for each coverslip. For each experiment, the average fluorescent intensity of all ROIs from a coverslip 
was normalized to the average fluorescent intensity of control samples in the same experiment. Pseudo-
color images were generated with ImageJ software (http://rsbweb.nih.gov/ij/). 
 
9. Fluorescent sensor imaging 
 
Fluorescence images in hippocampal neurons transfected with biSyn-GFP-Tom were taken with a Nikon 
A1 scanning confocal microscope equipped with a 10X air-objective (NA 0.45). GFP was excited with a 
488 nm diode laser and fluorescence collected with a 525/50 nm band-pass emission filter. tdTomato was 
excited with a 546 nm diode laser and fluorescence was collected with a 595/50 nm band-pass emission 
filter. All excitation and acquisition parameters (laser intensity, PMT offset and gain) were keep constant 
throughout experiments. Images were automatically acquired with NIS-Elements software from 9 fields 
of view (arranged in a 3x3 array) for each coverslip, 
Image analysis was semi-automatically performed with NIS-Elements software with the “Object Count” 
and the “Automatic Measurement Results” tools. ROIs were automatically detected on neuronal cell 
bodies using a fixed intensity threshold on the red channel. To calculate GFP/tdTomato ratio, the mean 
fluorescence intensity of GFP and tdTomato were measured for each ROI. For each experiment, the 
average GFP/tdTomato ratio of all ROIs from a coverslip was normalized to the average fluorescent 
intensity of control samples (WT neurons transfected with biSyn-GFP-Tom NKCC1-3’UTR plasmid and 
control miR) in the same experiment. Pseudo-color images of GFP/tdTomato ratio shown in figure 14, 18 
and 19 were generated with NIS-Elements software (Nikon).   
 
10. Luciferase assay  
 
Luciferase measurements were performed with Dual-luciferase assay kit (Promega), following the 
manufacturer’s instructions on a Victor 3 plate reader (Perkin Elmer). Briefly, neurons were lysed in the 
provided lysis buffer and firefly luciferase luminescence was measured after addition of its specific 
substrate. Then, renilla luciferase luminescence was measured upon addition of Stop and Glow substrate 
(that also inhibits firefly luciferase activity).  
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11. Micro-Electrode Array recordings 
 
Microelectrode arrays (Multichannel Systems, Germany) consisted of 60 TiN/SiN planar round electrodes 
(30 μm diameter; 200 μm center-to-center inter-electrode distance) divided into 6 separated wells. Each 
well contained 9 recording electrodes, arranged in a 3 × 3 square grid, and one big ground electrode. The 
activity of all cultures was recorded by means of the MEA60 System. After 1200x amplification, signals 
were sampled at 10 kHz and acquired through the data acquisition card and MC-Rack software 
(Multichannel Systems). To reduce thermal stress of the cells during the experiment, MEAs were kept at 
37 °C through a controlled thermostat (Multichannel Systems) in an experimental setup equipped with a 
custom-made incubator chamber (maintaining an humidified atmosphere consisting of 95% air and 5% 
CO2). All recordings were carried out in culture maintained in their original medium. Cultures were 
transferred to the recording setup and acclimatized for 20 minutes before beginning the recordings to 
allow the culture to adapt to the new environment and reach a stable level of activity 189-191. 
Spontaneous network activity of cultures was first recorded for 30 minutes. To assess the synchronicity of 
the neuronal networks, we computed the cross-correlation function between each pair of spike trains 
recorded from active channels. The cross-correlation function represents the probability of observing a 
spike in one channel i at time (t+τ, τ=3 ms) given that there is a spike in a second channel i+1 at time t. To 
quantify the strength of correlation between each pair of electrodes, we evaluated the correlation peak 
(Cpeak).  
Spontaneous bursting activity was detected using a custom burst detection method 192,193. According to 
those algorithms, in order to detect bursts, two thresholds were fixed: the first one was the maximum 
inter-spike interval (ISI) allowed for spikes within a burst (maxISI, usually set at 100 ms); the second one 
was defined as the minimum number of consecutive spikes belonging to a burst (minSpikes, usually set at 
5).  
After recording basal activity, bicuculline (BIC) or GABA (both 20 μM; Sigma) were applied and activity 
was recorded for an additional 30 minutes. The drugs were added to the bath solution by directly pipetting 
in the medium. Since we noticed that mechanical perturbation due to the pipette injection in the medium 
could cause a temporary instability of the firing rate, we discarded the first 10 minutes at the beginning of 
the 30-minutes recording phase. 
Data analysis was performed off-line with Matlab software (The Mathworks, USA) using the custom 
software package SPYCODE 194. The steps in the analysis are described briefly below.  
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Raw traces were high-pass-filtered (>300 Hz) to isolate spikes from the low fluctuation of the signal 
(LFP). We computed the spike detection as previously described 195. 
To characterize the activity level of the analyzed networks, we calculated the mean firing rate (MFR), 
which is defined as the mean number of spikes per second measured over the total recording time. We 
considered electrodes active if they recorded a firing rate greater than 0.02 spikes per second. The low 
threshold guarantees that only electrodes that are not covered by cells and those with very few spikes are 
excluded and that all others are retained.  
We computed the percentage of variation with respect to basal condition for each active electrode as 
follows: 




In order to evaluate statistical differences in MFR variation for each recorded channel, and to avoid 
setting an arbitrary threshold of significance, we used bootstrap method.196 
For the bootstrap analysis, the peak train for each time segment (basal or drug) was divided into 1-minute 
bins. The MFRs recorded during each 1-minute bin for the two time segments for each well were 
randomly shuffled into two groups for 10,000 times. The differences between the means of the randomly 
shuffled groups produced a null distribution (Fig. 5). For each channel, we computed the real difference 
between the basal and the drug values and assessed whether it fell outside the 95% confidence interval of 
the null distribution. 






12. Animals  
 
Ts65Dn colony 41 was maintained by crossing Ts65Dn female to C57BL/6JEi x C3SnHeSnJ (B6EiC3) F1 
males (Jackson Laboratories; Bar Harbor, USA). Animals were genotyped by PCR as previously 
described 197. A veterinarian was employed to monitor health and comfort of the animals. Mice were 
housed in a temperature-controlled room with a 12:12 hour dark/light cycle and ad libitum access to water 
and food.  
 
Figure 5: Bootstrap analysis method. The spike train for each channel was measured in 1-minute bins and shuffled 
10,000 times. The differences between the means of the two randomly shuffled groups produced a null distribution. 
For each channel, we computed the real difference between the basal and the drug values and assessed whether it fell 
outside the 95% confidence interval of the null distribution. 
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13. Statistical analysis  
 
Except where otherwise stated, the results are presented as the means ± SEM. Statistical analysis was 
performed using SigmaPlot (Systat) or GraphPad (Prism) software. Where appropriate, the statistical 
significance was assessed using the following parametric test: paired Student's t-test, two-way ANOVA 
or two-way repeated-measures (RM) ANOVA followed by all pairwise Turkey’s post hoc test. In case 
normal distribution or equal variance assumptions were not valid, statistical significance was evaluated 
using Wilcoxon signed-rank test (non-parametric) or two-way ANOVA and two-way RM-ANOVA on 
ranked transformed data. P values < 0.05 were considered significant.  
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RESULTS 
 
1. NKCC1 expression in trisomic neuronal culture 
 
Previous reports have indicated that NKCC1 chloride importer is upregulated in brains from Ts65Dn mice 
and Down syndrome persons 114. Since chloride homeostasis regulated by NKCC1 expression levels 
influences cognitive behaviors, we were interested in understanding the cause of NKCC1 upregulation. 
As a first step, we assessed whether NKCC1 is upregulated also in Ts65Dn neurons in culture.  To this 
aim, we analyzed the levels of NKCC1 protein in hippocampal and cortical primary neuronal cultures 
prepared from WT and Ts65Dn mice. At 15 days in vitro (DIV), neurons were lysed and NKCC1 protein 
expression was measured by western immunoblot. In line with previous in vivo results 114, western 
immunoblot analysis showed that the upregulation of NKCC1 is reproduced in both cortical and 





Figure 6: NKCC1 expression is increased in Ts65Dn cultured neurons. (A) Top: Representative immunoblot for 
NKCC1 in protein extracts from Ts65Dn and WT cortical neurons at 15 DIV. Bottom: Quantification of NKCC1 
protein (expressed as percentage of WT neurons) showed increased NKCC1 expression in Ts65Dn compared to WT 
cortical neurons. Actin was used as loading control. (B) Top: Representative immunoblot for NKCC1 in protein 
extracts from Ts65Dn and WT hippocampal neurons at 15 DIV. Bottom: Quantification of NKCC1 protein (expressed 
as percentage of WT neurons) showed increased NKCC1 expression in Ts65Dn compared to WT hippocampal 
neurons. Actin was used as loading control. All data shown are means (± SEM). Each dot represents a single well 
obtained from 9 independent neuronal cultures. *p<0.05; *** p<0.001, unpaired Student’s t-test.  
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These data indicate that primary cultures reproduce the phenotype observed in vivo, representing a 
suitable model to investigate the molecular mechanisms responsible for NKCC1 upregulation in DS. 
Interestingly, analysis of either NKCC1 mRNA expression by Real-Time quantitative PCR (RT-qPCR) or 
protein expression by immunoblot in primary cortical astrocyte cultures from WT and Ts65Dn mice did 
not show any significant difference (Fig. 7), indicating that altered regulation of NKCC1 expression is 










Since previous studies have shown that the expression of NKCC1 and KCC2 are developmentally 
regulated during neuronal maturation 55,198, we next evaluated the expression of both the cotransporters in 
Ts65Dn neurons during development between 2 and 21 DIV. We found that NKCC1 was expressed at all 
timepoints and significantly increased in Ts65Dn neurons at both 15 and 21 DIV. In contrast, KCC2 
expression was almost undetectable at 2 DIV, and strongly increased thereafter. Interestingly, KCC2 
expression appeared to be similar in the two groups between 7 and 21 DIV (Fig. 8). 
Figure 7: Similar NKCC1 mRNA and protein expression in cortical astrocyte cultures from WT and 
Ts65Dn mice. (A) RT-qPCR analysis of NKCC1 mRNA (expressed as fold over WT cells) showed similar 
NKCC1 expression in Ts65Dn compared to WT astrocytes. (B) Top: Representative immunoblot for NKCC1 in 
protein extracts from Ts65Dn and WT astrocytes at 15 DIV. Bottom: Quantification of NKCC1 protein (expressed 
as percentage of WT cells) showed similar NKCC1 expression in Ts65Dn compared to WT astrocytes. Actin was 
used as loading control. All data shown are means (± SEM). Each dot represents a single well obtained from 4 
independent  cultures.  
 











Figure 8: NKCC1 expression is increased in Ts65Dn neuronal cultures during development.  (A) 
Representative immunoblot for NKCC1 and KCC2 in protein extracts from Ts65Dn and WT at different time 
points during neuronal development. (B) Quantification of NKCC1 protein (expressed as percentage of WT 
neurons at each time point) showed increased expression in Ts65Dn compared to WT neurons at both 15 and 21 
DIV. Actin was used as loading control. (C) Quantification of KCC2 protein (expressed as percentage of WT 
neurons at each time point) showed similar expression in Ts65Dn compared to WT neurons in all time points. 
Actin was used as loading control. All data shown are means (± SEM). Each dot represents a single well obtained 
from 3 independent neuronal cultures. *p<0.05; ** p<0.01, unpaired Student’s t-test.  
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2. NKCC1 upregulation causes intracellular chloride accumulation in Ts65Dn 
neurons. 
 
To get insights into the functional consequences of NKCC1 upregulation in DS, we developed a 
Lentiviral-based RNA-interference (RNAi) strategy based on the expression of artificial microRNAs 
(amiR) to knockdown NKCC1 expression in trisomic neurons. We tested two different amiR sequences 
for their ability to reduce NKCC1 expression in WT and Ts65Dn neurons in culture. As shown in Fig. 9, 







Figure 9: Lentiviral-based RNAi strategy reduces NKCC1 protein expression in both Ts65Dn and WT 
neuronal cultures. (A) Schematic representation of the lentiviral vector (LV) expressing either control or NKCC1 
amiRs from the ubiquitous hPGK1 promoter. (B) Representative immunoblot for NKCC1 in protein extracts from 
LV-transduced Ts65Dn and WT neurons at 15 DIV. (C) Quantification of NKCC1 protein (expressed as 
percentage of WT neurons transduced with control amiR) showed increased NKCC1 expression in Ts65Dn 
compared to WT neurons. Expression of amiRs #1 and #2 induced significant NKCC1 knockdown in both WT and 
Ts65Dn neurons. Actin was used as internal standard. All data shown are means (± SEM). Each dot represents a 
single well obtained from 4 independent neuronal cultures. Two-way ANOVA:  genotype [F1,29=3.503, P=0.074]; 
treatment [F2,29=19.942, P<0.001]; genotype x treatment [F2,29= 2.256, P=0.127]. *p<0.05; **p<0.01; *** p<0.001, 
Two-way ANOVA followed by Tukey post hoc test. 
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Next, we measured changes in [Cl−]i with the green fluorescent chloride-sensitive dye MQAE following 
NKCC1 knockdown in primary hippocampal neurons at 15 DIV. MQAE fluorescence is quenched by the 
presence of chloride ions. Therefore, an increase in [Cl−]i is detected as a decrease in fluorescent signal. 
For these experiments, we expressed the NKCC1 amiRs together with the red fluorescent protein 
mCherry from the neuron-specific promoter hSyn (human Synapsin) to allow manipulation of [Cl−]i   
selectively in neurons and its measurement by MQAE imaging. Intensity of fluorescence was measured 
on the cell bodies, to exclude the influence of the number of neurons present in different fields of view on 
mean fluorescence intensity. As previously reported for Ts65Dn brain slices 73, Ts65Dn cultured neurons 
transduced with control amiR  showed decreased MQAE fluorescence (mirror of a higher [Cl-]i) 
compared to WT cells. Interestingly, NKCC1 knockdown by both amiRs significantly decreased [Cl-]i in 
Ts65Dn neurons, indicating that NKCC1 upregulation drives intracellular chloride accumulation in 









Figure 10: NKCC1 knockdown restores [Cl-]i in Ts65Dn neurons (A) Top: Schematic representation of the LV 
expressing either control or NKCC1 amiRs from the neuron-specific hSyn promoter. Bottom: Representative images of 
LV-transduced WT and Ts65Dn hippocampal neurons at 15 DIV (expressing mCherry; red) during imaging 
experiments with the chloride-sensitive dye MQAE (pseudo-colors). Fluorescent intensity of the dye (color-coded on 
the bottom) is inversely proportional to [Cl-]i. (B) Quantification of [Cl-]i with MQAE (expressed as percentage of WT 
neurons transduced with control amiR) showed lower fluorescent intensity (i.e. higher [Cl-]i) in Ts65Dn compared to 
WT neurons. NKCC1 knockdown by amiRs #1 or #2 significantly increased MQAE fluorescent intensity (i.e. decreased 
[Cl-]i) in both WT and Ts65Dn neurons. All data shown are means (± SEM).Each dot represents a single coverslip 
obtained from 6 independent neuronal cultures. Two-way ANOVA:  genotype [F1,48=0.394, P=0.533]; treatment 
[F2,48=29.601, P<0.001]; genotype x treatment [F2,48=1.891, P=0.163].. *p<0.05; **p<0.01; *** p<0.001, Two-way 
ANOVA followed by Tukey post hoc test. 
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3. Post-transcriptional regulation of NKCC1 expression in trisomic neurons. 
 
As a first step in dissecting the mechanisms of NKCC1 regulation, we measured NKCC1 mRNA 
levels by RT-qPCR. In line with previous in vivo results in Ts65Dn mouse brains 114, we found that 
the expression of NKCC1 mRNA was similar between Ts65Dn and WT cortical and hippocampal 
primary neurons (Fig. 11). These results suggest that increased NKCC1 expression in Ts65Dn 









Increased NKCC1 protein expression in trisomic neurons could also be potentially due to a slower 
turnover rate in Ts65Dn cells. To compare NKCC1 protein degradation rate in trisomic and WT neurons, 
we treated the cultures with Cycloheximide (Chx) to inhibit protein synthesis. Then we analyzed NKCC1 
expression at two different time points (12 and 24 hours later). Surprisingly, we found that NKCC1 
protein turnover rate in trisomic neurons was actually faster than in WT neurons (Fig. 12). Indeed, the 
slope of best-fit linear regression line for Ts65Dn samples was significantly different from the one 
Figure 11: Similar NKCC1 mRNA expression in cortical and hippocampal neuronal cultures from WT and 
Ts65Dn mice. (A) RT-qPCR analysis of NKCC1 mRNA (expressed as fold over WT cells) showed similar 
NKCC1 expression in Ts65Dn compared to WT cortical neurons at 15 DIV. All data shown are means (± SEM). 
Each dot represents a single well obtained from 4 independent neuronal cultures (B) RT-qPCR analysis of NKCC1 
mRNA (expressed as fold over WT cells) showed similar NKCC1 expression in Ts65Dn compared to WT 
hippocampal neurons at 15 DIV. All data shown are means (± SEM). Each dot represents a single well obtained 
from 2 independent neuronal cultures. 
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obtained for WT samples. Therefore, NKCC1 upregulation in Ts65Dn neurons does not seem to originate 









Having established that increased NKCC1 protein expression in Ts65Dn neurons does not depend on 
differences in mRNA transcription or protein turnover, we hypothesized that the observed difference 
could depend on mechanisms affecting translationTranslational regulation often takes place at 3’ 
untranslated regions (3’UTR) of genes. Considering that NKCC1 mRNA is characterized by the presence 
of a large 3’UTR (~2.8 kb) with a relatively high degree of conservation among mammals, we performed 
dual luciferase assay to test the influence of NKCC1 3’UTR on NKCC1 expression levels. To this aim, 
we cloned NKCC1 3’UTR downstream of Renilla luciferase (Rluc) in the psiCHECK2 plasmid, which 
also expresses Firefly luciferase (Fluc) as internal control. With this system, changes in the Rluc/Fluc 
ratio reflects the degree of post-transcriptional regulation exerted by the 3’UTR of NKCC1. Although this 
assay showed high variability, Ts65Dn cultures displayed a significantly higher value of the Rluc/Fluc 
ratio compared to WT. This was indicative of a loss of post-transcriptional repression exerted on the 
3'UTR, which would result in enhanced NKCC1 expression in trisomic neurons (Fig. 13).  
Figure 12: NKCC1 protein turnover rate is increased in Ts65Dn neurons. (A) Representative immunoblot for 
NKCC1 in protein extracts from Ts65Dn and WT neurons at 15 DIV after Cycloheximide (Chx) treatment for 12 
or 24 hours. (B) Quantification of NKCC1 protein (expressed as percentage of WT neurons treated with DMSO) 
showed faster NKCC1 turnover in Ts65Dn neurons compared to WT. Actin was used as internal standard. All data 
shown are means (± SEM). Slope of the best-fit linear regression line was -0.712 ± 0.139 for WT and -1.546 ± 
0.007 for Ts65Dn. Slopes were significantly different (P=0.027). Two-way ANOVA: genotype [F1,57=88.783, 
P<0.001]; treatment [F2,57=7.480, P=0.001]; genotype x treatment [F2,57=0.0429 ,P=0.958]. *p<0.05; *** p<0.001, 
Two-way ANOVA followed by Tukey post hoc test. 





We reasoned that the high variability observed in this assay could derive from two different sources. First, 
both Rluc and Fluc are expressed from ubiquitous promoters that will be active in both neurons and 
astrocytes in culture. Although, our neuronal cultures show   1̴0% astrocytes, these are transfected to high 
rate, therefore complicating the interpretation of the results. Second, the expression of Rluc and Fluc in 
this plasmid are under the control of two different promoters that could have different activity in different 
cell types including WT versus Ts65Dn neurons. To circumvent these limitations, we developed a neuro-
specific sensor in which two identical transcription cassettes drive the expression of GFP and tdTomato 
fluorescent proteins under the control of the same neuron-specific Synapsin (Syn) promoter. In this 
sensor, NKCC1 3'UTR is cloned downstream of GFP while tdTomato serves as an internal control to 
normalize for transfection efficiency. Upon transfection in neurons, the GFP/tdTomato fluorescent signal 
ratio reflects the extent of translational repression exerted by NKCC1 3’UTR. With this assay, we 
confirmed the results obtained with the luciferase assay. Indeed the GFP/tdTomato ratio was significantly 
higher in trisomic neurons, indicating an impairment of post-transcriptional repression exerted on 
NKCC1-3’UTR (Fig 14). 
Figure 13: Post-transcriptional regulation of NKCC1 3’UTR drives increased expression in Ts65Dn 
neurons. Top: Scheme of the psiCHECK2 dual-luciferase plasmid used to assess NKCC1 3’UTR activity. 
Bottom:  Rluc/Fluc ratio was increased in Ts65Dn neurons compared to WT. For each box plot, the central line 
indicates the median and the box limits indicate the 25th and 75th percentiles. Whiskers represent the 5th and the 
95th percentiles. Number in parenthesis indicates the number of analysed samples for each experimental group 
obtained from 10 independent neuronal cultures. *p<0.05, unpaired Student’s t-test. 









Using the fluorescent sensor we found that the difference between WT and Ts65Dn in the ratio 
GFP/tdTomato was smaller than the difference in RLuc/FLuc obtained with luciferase assay. However, it 
should be noted that luciferase assay is affected by a greater variability compared to the measurement of 
fluorescence, probably due to the presence of signal collected from transfected astrocytes. Conversely, 
luciferase bioluminescence displays a wider dynamic range of measurement compared to fluorescence, 
partly explaining the smaller difference observed in Ts65Dn neurons compared to WT when performing 





Figure 14: Post-transcriptional regulation of NKCC1 3’UTR drives increased expression in Ts65Dn 
neurons. (A) Scheme of the neuro-specific fluorescent sensor used to assess NKCC1 3’UTR repression activity. 
(B) Representative pseudo-color images of GFP/tdTomato ratio in WT and Ts65Dn neurons. (C) GFP/tdTomato 
ratio was increased in Ts65Dn neurons compared to WT. For each box plot, the central line indicates the median 
and the box limits indicate the 25th and 75th percentiles. Whiskers represent the 5th and the 95th percentiles. 
Number in parenthesis indicates the number of samples analyzed for each experimental group, deriving from 8 
independent neuronal cultures. **p<0.01, unpaired Student’s t-test. 
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4. microRNAs play a role in NKCC1 upregulation 
 
Since 3'UTRs are the preferred site of action of microRNAs, we investigated the possible involvement of 
this class of regulatory noncoding RNAs in NKCC1 upregulation in trisomic neurons. To this aim, we 
inhibited microRNAs repressive activity by knockdown of the GW182 family member Tnrc6C 
(trinucleotide repeat containing protein 6C), an essential component of the RISC complex required for 
miRNA-dependent repression of translation of complimentary mRNAs 134 (Fig.15A). We transfected WT 
and Ts65Dn neurons with a specific short-interfering RNA (siRNA) and then assessed the changes in 
NKCC1 levels by western immunoblot. We found that Tnrc6C knockdown increased NKCC1 protein 







Figure 15: Tnrc6C regulates NKCC1 expression. (A) RT-qPCR analysis showed that Tnrc6C mRNA 
expression was significantly decreased after siRNA-mediated knockdown. All data shown are means (± SEM). 
Each dot represents a single well, obtained from 3 independent neuronal cultures. Two-way ANOVA: genotype 
[F1,29=7.417, P=0.011]; treatment [F1,29=31.960, P<0.001]; genotype x treatment [F1,29=0.144 ,P=0.707]. (B) Left: 
Representative immunoblot for NKCC1 in protein extracts from Ts65Dn and WT neurons upon Tnrc6C 
knockdown. Right: Quantification of NKCC1 protein (expressed as percentage of WT neurons treated with control 
siRNA) showed higher NKCC1 expression after Tnrc6C knockdown in both Ts65Dn and WT neurons. Actin was 
used an internal standard. All data shown are means (± SEM). Each dot represents a single well, obtained from 8 
independent neuronal cultures. Two-way ANOVA: genotype [F1,66=103.031, P<0.001]; treatment [F1,66=13.629, 
P<0.001]; genotype x treatment [F1,66=0.0296 ,P=0.864]. *p<0.05; *** p<0.001, Two-way ANOVA followed by 
Tukey post hoc test. 
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After demonstrating that microRNAs are involved in NKCC1 regulation, we performed a bioinformatic 
analysis to predict potential miRNAs binding sites on NKCC1 3'UTR with TargetScan software 199 
(Fig.16A). We found  that several microRNAs are predicted to target NKCC1 3’UTR. In order to identify 
possible candidates microRNA (expressed at lower levels in trisomic samples) that could drive NKCC1 
upregulation, we next performed an initial screening by RT-qPCR of the expression level of  ̴ 70 miRNAs 







Figure 16: Screening of potential miRNAs targeting NKCC1 3’ UTR (A) TargetScan analysis of potential 
miRNAs binding sites on NKCC1 3'UTR. (B) Heat-map showing miRNA expression of different microRNAs in the 
hippocampus of WT and Ts65Dn mice. 
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We found that miR497a-5p and miR101-3p were downregulated in Ts65Dn brains compared to WT. To 
confirm the results of this preliminary screening, we next assessed the expression of these two candidate 
miRNAs in primary neuronal cultures. Moreover, since miR497a-5p is a representative of a larger family 
of microRNAs sharing a nearly identical seed sequence, we also evaluated expression of other cognate 
miRNAs. RT-qPCR results showed that miR101-3p and miR497a-5p levels were in fact decreased in both 
Ts65Dn brains and neuronal cultures. We also found that miR15a-5p and miR15b-5p were decreased only 
in trisomic neuronal cultures (Fig. 17A and B). Interestingly, expression analysis in post-mortem human 





Fig.17: Expression of miR497a-5p and miR101-3p (A) RT-qPCR analysis showed the expression of miR497a-5p 
and miR101-3p was reduced in Ts65Dn hippocampus compared WT. (B) Expression of miR497a-5p, mir15a-5p, 
miR15b-5p and miR101-3p was reduced in Ts65Dn neuronal cultures compared WT. (C) Expression of miR497a-
5p was reduced in the hippocampus of human DS patients compared to age/sex-matched controls. All data shown 
are means (± SEM). Each dot represents a single sample. For results shown in (B), samples derived from 3 
independent neuronal cultures. *p<0.05, **p<0.01 unpaired Student’s t-test. 
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5. Candidate microRNAs target NKCC1-3'UTR 
 
In order to demonstrate the interaction of miR497a-5p and miR101-3p with NKCC1 3’UTR and evaluate 
their repression activity, we transfected the fluorescent NKCC1 3’UTR sensor in WT and Ts65Dn 
neurons together with candidate microRNA mimics. MicroRNA mimics are short, chemically modified 
double-stranded RNAs that mimic endogenous miRNAs. They are commonly used for functional analysis 
of microRNA activity by overexpression. We found that overexpression of miR497a-5p mimic effectively 
reduced the GFP/tdTomato ratio (mirroring reduced NKCC1 translation) in both WT and Ts65Dn 
neurons (Fig. 18 B and 19 B). Overexpression of miR101-3p mimic significantly decreased NKCC1 
translation only in trisomic neurons (Fig. 18 D and 19 D) 
Next, to study the interaction of endogenous microRNAs with NKCC1 3’UTR, we mutated NKCC1 
3’UTR in the seed-binding sequences of miR101-3p and miR497a-5p to perturb miRNA-mRNA 
interaction and consequently prevent target repression.  
Bioinformatics analysis with TargetScan predicted two biding sequences for miR497a-5p at position 1883 
and 2636 (hereafter referred to as seed sequence number 1 and 2, respectively) and one miR101-3p 
binding site at position 2578 on NKCC1 3'UTR. In WT neurons, one by one mutation of the three seed 
sequences caused a significant increase in the GFP/tdTomato ratio. This indicated that the endogenous 
candidate microRNAs bind to NKCC1-3’UTR and exert a negative regulation of expression (Fig. 18 B 
and D). However, in trisomic neurons, none of the mutations produced a significant impact on GFP 
expression. This again pointed to impaired regulation exerted by these microRNAs in DS, probably due to 
their lower expression (Fig. 19 B and D). Moreover, mutation of the seed-binding sequence for miR101-
3p and seed-binding sequence number 2 for miR497a-5p could prevent the interaction of exogenous 
microRNA mimics on NKCC1 3’UTR, abolishing their effect in both WT and Ts65Dn neurons (Fig. 18B 
and fig. 19B and D). This confirmed the site of action of both microRNA. Conversely, overexpression of 
miR497a-5p retained partial activity after mutation of its seed-binding sequence number 1 both in WT 
and Ts65Dn neurons. This indicated that this site probably plays a minor role in the interaction with the 
microRNA and in translational repression compared to binding sequence number 2 (Fig.18B and 19B).  
 




Figure 18: miR-497a-5p and miR-101-3p regulate NKCC1 expression in WT neurons. (A) Pseudo-color images 
of GFP/tdTomato ratio representing the interaction of miR497a-5p with native or mutated NKCC1 3’UTR (B) 
Mutation of miR497a-5p seed-binding sequences increases GFP/tdTomato ratio.  Two-way ANOVA: sensor 
[F2,136=41.827, P<0.001]; microRNA [F1,136=10.011, P=0.002]; sensor x microRNA [F2,136=4.020, P=0.020]. (C) 
Pseudo-color images of GFP/tdTomato ratio representing the interaction of miR101-3p with native or mutated 
NKCC1-3’UTR. (D) Mutation of miR101-3p seed-binding sequence increases GFP expression in wild-type neurons. 
Two-way ANOVA: sensor [F1,84=10.232, P=0.02]; microRNA [F1,84=1.884, P=0.174]; sensor x microRNA 
[F1,84=0.0508, P=0.822]. For each box plot, the central line indicates the median and the box limits indicate the 25th 
and 75th percentiles. Whiskers represent the 5th and the 95th percentiles. Number in parenthesis indicates the number 
of samples for each experimental group, obtained from 12 independent neuronal cultures. *p<0.05; **p<0.01;*** 
p<0.001, Two-way ANOVA followed by Tukey post hoc test. 




Figure 19: miR497a-5p and miR101-3p regulate NKCC1 expression in Ts65Dn neurons. (A) Pseudo-color images 
of GFP/tdTomato ratio representing the interaction of miR497a-5p with native or mutated NKCC1-3’UTR. (B) 
Overexpression miR497a-5p decreased GFP/tdTomato ratio by interacting mainly with seed-binding sequence number 
2. Two-way ANOVA: sensor [F2,118=11.834, P<0.001]; microRNA [F2,118=7.583, P=0.007]; sensor x microRNA 
[F2,118=3.185, P=0.045]. (C) Pseudo-color images of GFP/tdTomato ratio representing the interaction of miR101-3p 
with native or mutated NKCC1-3’UTR. (D) Overexpression of miR101-3p decreased GFP/tdTomato ratio. Two-way 
ANOVA: sensor [F1,80=5.670, P=0.020]; microRNA [F1,80=8.207, P=0.005]; sensor x microRNA [F1,80=2.126, 
P=0.149]. For each box plot, the central line indicates the median and the box limits indicate the 25th and 75th 
percentiles. Whiskers represent the 5th and the 95th percentiles. Number in parenthesis indicates the number of 
samples for each experimental group, deriving from 12 independent neuronal cultures. *p<0.05; **p<0.01;*** 
p<0.001, Two-way ANOVA followed by Tukey post hoc test. 
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6. miR497a-5p and miR101-3p regulate chloride levels in primary neurons 
through the downregulation of NKCC1 expression 
 
To finally investigate whether miR497a-5p and miR101-3p can eventually indeed regulate NKCC1 
protein expression, we transfected candidate miRNAs mimics in primary cortical neurons and then 
performed western immunoblots to assess NKCC1 protein levels. We found that the exogenous delivery 
of both microRNAs significantly decreased NKCC1expression levels in trisomic neurons, restoring 
physiological level similar to the one of WT cells. Interestingly, simultaneous transfection with a 1:1 
mixture of the two microRNA (to maintain unaltered the total amount of transfected mimics) did not elicit 
an additive effect on NKCC1 downregulation (Fig.20). This indicates that the action of the two 
microRNAs is not synergistic. Conversely, overexpression of the candidate microRNAs showed a minor 
effect, with only miR497a-5p demonstrating a small, but significant NKCC1 downregulation in WT 
neurons.  
 
Fig.20: miR497a-5p and miR101-3p regulate NKCC1 protein expression in Ts65Dn neurons. Top: 
Representative immunoblot for NKCC1 in protein extracts from Ts65Dn and WT neurons upon miR497a-5p and 
miR101-3p transfection. Bottom: Quantification of NKCC1 protein (expressed as percentage of WT neurons treated 
with control mimic) showed NKCC1 downregulation mainly in Ts65Dn neurons after miR497a-5p and miR101-3p 
overexpression. GAPDH was used as internal standard. All data shown are means (± SEM). Each dot represents a 
single well of neurons, obtained from 15 independent neuronal cultures. Two-way ANOVA: genotype 
[F1,157=22.639, P<0.001]; treatment [F3,157=9.060, P<0.001]; genotype x treatment [F3,157=0.385, P=0.764]. 
*p<0.05; **p<0.01; *** p<0.001, Two-way ANOVA followed by Tukey post hoc test. 
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To further strengthen these findings, we next performed the reverse experiment. We transfected short 
synthetic, single-stranded oligonucleotides (termed microRNA inhibitors) designed to bind and inhibit the 
interaction of endogenous miRNAs to their targets. Delivery of both anti-miR497a-5p or anti-miR101-3p 
inhibitors significantly increased NKCC1 protein expression in WT neurons, while displaying no effect 
on Ts65Dn neurons (Fig.21). This was likely because endogenous signaling by these microRNA is 
already impaired in trisomic cells. Importantly, these results are in line with the increase in GFP 
translation observed in experiments with the fluorescent sensor after mutating microRNAs seed-binding 







Fig.21: Delivery of miRNA inhibitors increase NKCC1 protein expression in WT neurons. Top: Representative 
immunoblot for NKCC1 in protein extracts from Ts65Dn and WT neurons upon miRNA inhibitors transfection. 
Bottom: Quantification of NKCC1 protein (expressed as percentage of WT neurons treated with control miRNA 
inhibitor) showed NKCC1 upregulation in WT but not Ts65Dn neurons after delivery of anti miR497a-5p and anti 
miR101-3p inhibitors. Actin was used as internal standard. All data shown are means (± SEM). Each dot represents 
a single well, obtained from 6 independent neuronal cultures. Two-way ANOVA: genotype [F1,71=76,308, 
P<0.001]; treatment [F2,71=5.978, P=0.004]; genotype x treatment [F2,71=3.384, P=0.040]. *p<0.05; *** p<0.001, 
Two-way ANOVA followed by Tukey post hoc test. 
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Finally, to investigate the functional consequences of candidate miRNAs overexpression on [Cl−]i, we 
assessed intracellular chloride concentration in cultured primary hippocampal neurons using the chloride 
sensitive dye MQAE, whose fluorescence is quenched by the presence of chloride ions. In line with 
previous results, we found that Ts65Dn neurons transfected with control microRNA display increased 
levels of intracellular chloride compared to WT. Exogenous delivery of both miRNAs restored 
physiological [Cl−]i in Ts65Dn neurons, without affecting chloride levels in WT neurons (Fig.22). 
Altogether, these results indicate that dysregulation of microRNAs in trisomic neurons leads to NKCC1 






Fig.22: Overexpression of miR497a-5p and miR101-3p restored [Cl-]i in Ts65Dn neurons. (A) Representative 
pseudo-color images of hippocampal neurons during intracellular Cl- imaging with the fluorescent chloride-sensitive 
dye MQAE. Fluorescent intensity of the dye (color-coded on the right) is inversely proportional to [Cl-]i. (B) 
Quantification of [Cl-]i with MQAE (expressed as percentage of WT neurons transduced with control miR) showed 
lower fluorescent intensity (i.e. higher [Cl-]i) in Ts65Dn compared to WT neurons. Overexpression of miR497a-5p 
and miR101-3p mimics restored [Cl−]i in Ts65Dn neurons. All data shown are means (± SEM). Each dot represents a 
single well, obtained from 4 independent neuronal cultures. Two-way ANOVA: genotype [F1,47=1.466, P=0.233]; 
treatment [F3,47=4.543, P=0.008]; genotype x treatment [F3,47=2.444, P=0.078]. *p<0.05; **p<0.01; Two-way 
ANOVA followed by Tukey post hoc test. 
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7. Overexpression of miR497a-5p and miR101-3p restore inhibitory GABAergic 
signaling in Ts65Dn neuronal networks 
 
As a next step, we evaluated whether restoring [Cl−]i in trisomic neurons through the overexpression of 
either miR497a-5p or miR101-3p could rescue GABAAR fully inhibitory signaling. To this aim, we used 
multi-electrode arrays (MEAs) to record the neuronal network activity from WT and Ts65Dn neurons in 
culture. First, we recorded basal neuronal activity at 16 DIV, three days after the transfection of miRNA 
mimics or the corresponding control. We found that the mean firing rate (MFR) and mean bursting rate 
(MBR) of action potentials were both increased in Ts65Dn compared to WT neuronal cultures (Fig.23 A 
and B). Interestingly, MFR and MBR were decreased in trisomic neuronal cultures transfected with 
miR101-3p mimic. Conversely, overexpression of miR101-3p mimic showed the opposite effect on MFR 
in WT neurons, while bursting activity was unchanged. Moreover, overexpression of miR497a-5p 
significantly decreased MBR of Ts65Dn neurons while having a smaller effect on MFR (Fig.23A and B). 
Interestingly, when we evaluated the firing synchrony of the neuronal network by measuring the peak of 
the cross-correlation function (C peak; see methods), we found that network synchrony was significantly 
lower in Ts65Dn networks compared to WT. However, overexpression of both microRNAs further 
decreased the synchrony of Ts65Dn cultures, broadening the difference between trisomic and WT 







Fig.23: miR497a-5p and miR101-3p regulate basal firing parameters in Ts65Dn neuronal cultures. (A) Increased firing 
frequency in Ts65Dn neurons is rescued by miR101-3p overexpression. Conversely, miR101-3p overexpression increased the 
spiking frequency in WT neurons. Two-way ANOVA: genotype [F1,1205=14.699, P<0.001]; treatment [F2,1205=1.380, P=0.252]; 
genotype x treatment [F2,1205=9.955, P<0.001]. (B) Increased burst rate in Ts65Dn neurons is rescued by overexpression of 
both miR497a-5p and miR101-3p, without affecting WT neurons. Two-way ANOVA: genotype [F1,585=0.158, P=0.691]; 
treatment [F2,585=2.237, P=0.108]; genotype x treatment [F2,585=6.760, P=0.001]. (C) Network synchronization is decreased in 
trisomic cultures. Overexpression of miR497a-5p and 101-3p further decreases synchrony in trisomic neurons while having no 
effect in WT networks. Two-way ANOVA: genotype [F1,3741=193.734, P<0.001]; treatment [F2,3741=10.708, P<0.001]; 
genotype x treatment [F2,3741=12.820, P<0.001]. *p<0.05; **p<0.01;*** p<0.001, Two-way ANOVA followed by Tukey post 
hoc test. All data shown are means (± SEM). Number in parenthesis indicates the number of electrodes recorded for each 
experimental group. Experiments were performed on 19 MEA for WT-miR-Control, 23 MEA for WT-miR497a, 17 MEA for 
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Next, we recorded changes in neuronal network activity before and after the administration of 
drugs modulating GABAergic transmission.  
At first, we tested whether overexpression of either microRNAs could restore inhibitory signaling upon 
bath application of exogenous GABA. We found that GABA application elicited a sharp decrease of MFR 
in virtually all recorded electrodes in WT hippocampal neurons. Conversely, only 75% of electrodes 
showed a decrease in MFR, while 13% showed even a significant increase in Ts65Dn hippocampal 
neurons (Fig. 24 A and B). This was indicative of a depolarizing effect of GABA. Accordingly, when we 
computed the mean ratio between MFR after GABA administration and basal MFR for each well, we 
noticed a significant increase of the ratio in Ts65Dn neurons transfected with control microRNA, 
compared to WT. However, since the majority of electrodes displayed decreased MFR, the mean MFR 
ratio computed on the whole well remained below 1, in spite of the presence of a population of neurons 
where GABAA receptor activation is depolarizing (Fig.24 C). Overexpression of either miR497a-5p or 
miR101-3p, achieved by transfection of microRNA mimics, completely rescued the inhibitory effect of 
exogenous GABA in Ts65Dn neurons returning MFR ratio to WT levels, and eliminating the population 
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Fig.24: Overexpression of miR497a-5p and miR101-3p restored exogenous inhibitory GABAergic signalling 
in Ts65Dn neurons. (A) Mean firing rate (MFR) comparison for each recorded electrode (plotted as a dot) in basal 
conditions and after treatment with GABA (20 M) in WT and Ts65Dn neurons. Dark and light grey dots indicate 
respectively electrodes showing a significant increase or decrease in the MFR. Black dots indicate electrodes 
showing no significant changes in MFR. Numbers of recorded MEA for each experimental group are indicated in 
the right top corner of each graph. (B) Quantification of the percentage of electrodes displaying an increase (dark 
grey) or decrease (light grey) in MFR after GABA administration showed a complete rescue of inhibitory signaling 
in Ts65Dn neurons upon overexpression of either miR497a-5p or miR101-3p. Data shown are means (± SEM). 
MFR increase, Two-way ANOVA: genotype [F1,67=3.528, P=0.065]; treatment [F2,67=3.342, P=0.042]; genotype x 
treatment [F2,67=6.342, P=0.042].MFR decrease, Two-way ANOVA: genotype [F1,67=3.388, P=0.072]; treatment 
[F2,67=3.713, P=0.032]; genotype x treatment [F2,67=3.713, P=0.032]. (C) Quantification of MFR ratio before and 
after GABA administration. For each box plot, central line represents the median and the box limits indicate the 
25th and 75th percentiles. Whiskers represent the 5th and the 95th percentiles. Number in parenthesis indicates the 
number of wells recorded for each experimental group. Two-way ANOVA: genotype [F1,67=8.261, P=0.006]; 
treatment [F2,67=8.478, P<0.001]; genotype x treatment [F2,67=1.383, P=0.259]. **p<0.01; *** p<0.001, Two-way 
ANOVA followed by Tukey post hoc test 
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We also performed the reverse experiment to test whether microRNAs overexpression could restore 
endogenous GABAergic inhibitory signaling as well.As expected, inhibition of endogenous GABAergic 
signaling with the GABAAR antagonist bicuculline (BIC) determined a significant increase of the MFR 
in 84% of active electrodes in WT cultures. Notably, in Ts65Dn neuronal network, application of 
bicuculline determined a decrease of MFR in 41% of electrodes, while only 48% showed an increase (Fig. 
25 A and B). In addition, mean ratio between MFR after treatment with bicuculline and basal MFR was 
significantly lower in Ts65Dn neuronal networks compared to WT (Fig.25C).  These results are 
consistent with the presence of a large population of trisomic neurons characterized by depolarizing 
GABAergic transmission. Importantly, in Ts65Dn cultures transfected with both miRNA mimics, the 
percentage of electrodes showing an increase in MFR upon bicuculline treatment and the mean value of 
MFR ratio were similar to the one seen in WT neurons. This indicates that endogenous inhibitory 
GABAergic signaling was restored (Fig 25).  
Altogether, the MEA experiments showed that miRNAs downregulation drives alteration in inhibitory 
GABAergic signaling in trisomic neuronal networks and that their overexpression restores physiological 
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Fig.25: Overexpression of miR497a-5p and miR101-3p restored endogenous inhibitory GABAergic signalling 
in Ts65Dn neurons. (A) Mean firing rate (MFR) comparison for each recorded electrode (plotted as a dot) in basal 
conditions and after treatment with bicuculline (20 M) in WT and Ts65Dn neurons. Dark and light grey dots 
indicate respectively electrodes showing a significant increase or decrease in the MFR. Black dots indicate 
electrodes showing no significant changes in MFR. Numbers of recorded MEA for each experimental group are 
indicated in the right top corner of each graph. (B) Quantification of the percentage of electrodes displaying an 
increase (dark grey) or decrease (light grey) in MFR after bicuculline administration showed a complete rescue of 
endogenous GABA inhibitory signaling in Ts65Dn neurons upon overexpression of either miR497a-5p or miR101-
3p. Data shown are means (± SEM). MFR increase, Two-way ANOVA: genotype [F1,66=4.109, P=0.047]; treatment 
[F2,66=2.737, P=0.073]; genotype x treatment [F2,66=6.484, P=0.003]. MFR decrease, Two-way ANOVA: genotype 
[F1,66=2.783, P=0.100]; treatment [F2,66=3.275, P=0.045]; genotype x treatment [F2,66=4.088, P=0.022].. (C) 
Quantification of MFR ratio before and after bicuculline administration. For each box plot, central line represents 
the median and the box limits indicate the 25th and 75th percentiles. Whiskers represent the 5th and the 95th 
percentiles. Number in parenthesis indicates the number of wells recorded for each experimental group. Two-way 
ANOVA: genotype [F1,57=1.473, P=0.23]; treatment [F2,57=5.671, P=0.006]; genotype x treatment [F2,57=6.456, 
P=0.003]. **p<0.01; *** p<0.001, Two-way ANOVA followed by Tukey post hoc test 
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8. Long-term overexpression of candidate microRNAs using viral vectors  
 
Envisaging in vivo experiments, we constructed an adeno-associated viral vector that allowed us to 
achieve long-term overexpression of candidate microRNAs. In the expression vector, microRNA mimics 
are ubiquitously expressed on the 3’ arm of the hairpin, under the control of the U6 promoter according to 
a previously described strategy that minimizes passenger-strand-mediated off-target effects 200. Upon 
transduction, we performed western immunoblot to check whether AAV-mediated delivery of miR497a-
5p and miR101-3p mimic was efficient in reducing NKCC1 levels. Similar to transient transfection with 
the same mimics, infection of cortical cultured neurons induced a significant decrease in NKCC1 levels in 
Ts65Dn neurons (Fig.26). In the next months, we will perform stereotaxic injection of these viral vectors 
in the hippocampus of Ts65Dn mice and WT littermates, aiming at reducing intracellular chloride 




Fig.26: AAV-mediated microRNA mimics delivery decreases NKCC1 expression in Ts65Dn neurons. (A) 
Scheme of the AAV vector plasmid used to overexpress miR497a-5p or miR101-3p mimics. (B) Top: Representative 
immunoblot for NKCC1 in protein extracts from Ts65Dn and WT neurons upon AAV-mediated miRNA mimic 
overexpression. Bottom: Quantification of NKCC1 protein (expressed as percentage of WT neurons transduced with 
control miR) showed NKCC1 downregulation in Ts65Dn neurons after delivery of miR mimics. GAPDH was used as 
internal standard. All data shown are means (± SEM). Each dot represents a single well, obtained from 5 independent 
cultures. Two-way ANOVA: genotype [F1,53=0.319, P=0.575]; treatment [F2,53=5.315, P=0.008]; genotype x 
treatment [F2,53=3.384, P=0.009]. *p<0.05; **p<0.01;*** p<0.001, Two-way ANOVA followed by Tukey post hoc 
test. 
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9. The DS-triplicated gene APP regulates NKCC1 in trans by competing for 
miR497a-5p and miR101-3p in Ts65Dn neurons 
 
How does genome triplication lead to microRNA dysregulation in DS? To try addressing this question, 
we hypothesized that the overexpressed genes from the DS-triplicated chromosomal region in Ts65Dn 
mice could act as competitive endogenous RNAs (ceRNAs) for microRNA also targeting NKCC1. 
Indeed, mRNAs bearing seed-binding sequences for the same microRNAs can influence each other 
expression by competing for microRNAs binding 201,202. Therefore, changes in the levels of one mRNA 
can influence the expression of other transcripts that share the binding site for the same microRNA. 
Bioinformatic analysis with TargetScan for possible DS-triplicated genes acting as ceRNAs, predicted 
three binding sites for candidate microRNAs on the 3’UTR of APP: one seed-binding sequence for 
miR497a-5p and two for miR101-3p. Accordingly, we found that AAV-mediated overexpression of both 







Fig.27: AAV-mediated overexpression of miR497a-5p and miR101-3p downregulate APP expression in 
Ts65Dn and WT neurons. (A) Scheme of the AAV vector plasmid used to overexpress miR497a-5p or miR101-3p 
mimics. (B) Top: Representative immunoblot for APP in protein extracts from Ts65Dn and WT neurons transduced 
with AAV vectors expressing miRNA mimic. Bottom: Quantification of APP protein (expressed as percentage of WT 
neurons transduced with control miR) showed APP downregulation in both WT and Ts65Dn neurons after delivery of 
miR mimics. GAPDH was used as internal standard. All data shown are means (± SEM). Each dot represents a single 
well, obtained from 5 independent cultures. Two-way ANOVA: genotype [F1,54=47.440, P<0.001]; treatment 
[F2,54=41.844, P<0.001]; genotype x treatment [F2,54=9.226, P<0.001].  *p<0.05;**p<0.01, *** p<0.001, Two-way 
ANOVA followed by Tukey post hoc test. 
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The ceRNAs hypothesis postulates that 3’UTRs, in addition to the action exerted in cis on the upstream 
coding sequence, can also act in trans by sequestering microRNAs and preventing them to repress other 
targets 201,202. Therefore, we thought that upregulation of the DS-triplicated gene APP could result in 
binding a higher amount of microRNAs, attenuating translational inhibition on other targets carrying 
seed-binding sequences for the same microRNAs, such as NKCC1 and Dyrk1A. To test this hypothesis, 
we designed a short interference RNA against APP and assessed possible changes in NKCC1 levels upon 
knockdown. Indeed, AVV-mediated APP knockdown caused a significant decrease in NKCC1 levels in 
trisomic neurons (Fig.28). Altogether, these data indicate that the DS-triplicated gene APP is targeted by 
the same microRNA regulating NKCC1 expression in neuron and that the expression level of the two 
proteins are related. This established a link between DS genomic triplication, microRNA dysregulation 
and NKCC1 upregulation and culminated in chloride homeostasis deficits and altered GABAergic 
signaling.  
Fig.28: APP knockdown decreases NKCC1 expression in Ts65Dn neurons. (A) Scheme of the AAV vector 
plasmid used to express APP shRNA. (B) Representative immunoblot for NKCC1 and APP in protein extracts from 
Ts65Dn and WT neurons upon APP shRNA expression. (C) Quantification of APP protein (expressed as percentage 
of WT neurons transduced with control shRNA) showed a marked APP downregulation in both WT and Ts65Dn 
neurons upon delivery of APP shRNA. GAPDH was used as internal standard. Two-way ANOVA: genotype 
[F1,19=3.200, P=0.093]; treatment [F1,19=80.000, P<0.001]; genotype x treatment [F1,19=7.200, P=0.016]. (D) 
Quantification of NKCC1 protein (expressed as percentage of WT neurons transduced with control shRNA) showed 
NKCC1 downregulation in Ts65Dn neurons after delivery of APP shRNA. GAPDH was used as internal standard. 
All data shown are means (± SEM). Each dot represents a single well, obtained from 2 independent cultures. Two-
way ANOVA: genotype [F1,19=1.180, P=0.293]; treatment [F1,19=10.178, P=0.006]; genotype x treatment 
[F1,19=9.012, P=0.008]. *p<0.05;** *** p<0.001, Two-way ANOVA followed by Tukey post hoc test. 
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DISCUSSION 
 
DS is caused by the triplication of human chromosome 21 (HSA21) and it is the most common genetic 
form of intellectual disability. Cognitive deficits are the major hallmark of DS and represent the most 
debilitating aspect of the pathology, highly impinging on life quality of DS people and their families. 
Studies on DS mouse models have identified many alterations to explain DS-related cognitive 
impairments 5,35. The Ts65Dn mouse is a widely used trisomic murine model of DS carrying a freely-
segregating extra chromosome containing ~55% of mouse orthologues genes to HSA21 41. Although the 
Ts65Dn model presents some genetic limitations compared to the human syndrome 18,197, it recapitulates 
many DS-related abnormalities, including craniofacial dysmorphic features, cognitive impairment and 
altered hippocampus-dependent memory functions 41,203,204. Currently, the Ts65Dn mouse is the only 
model that has been exploited for preclinical evaluation of pharmacotherapy for cognition in DS 36. A 
number of studies have evaluated the contribution of different HSA21-derived genes to DS-related 
cognitive impairment by genetically restoring disomy of some triplicated genes or pharmacologically 
reducing their activity in Ts65Dn mice. In particular, much of the work on triplicated HSA21 orthologues 
in Ts65Dn mice has focused on a small set of genes:  App 205-207, Girk2 208,209, the dual specificity 
tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A)210-212, the bHLH transcription factors 
Olig1/Olig2 90, and the phosphoinositide phosphatase synaptojanin 1 (Synj1)213. These studies have 
clearly showed that specific DS-related phenotypes critically arise from the triplication of different 
HSA21 dosage-sensitive genes in Ts65Dn mice. However, transcriptome profiling in brains of both 
Ts65Dn mice and DS patients have highlighted global gene expression dysregulation of hundreds of non-
HSA21 transcripts as a secondary consequence of trisomy 25,32,214, greatly complicating the understanding 
of the underling neurophysiological alterations leading to cognitive disabilities 24. In fact, although 
HSA21 does not contain any gene encoding for GABA receptors, a large body of evidence has pointed to 
altered signaling from GABAARs and excitatory/inhibitory synaptic imbalance as major players in 
cognitive impairment in Ts65Dn mice 72,84,86,90,96. In this framework, we have recently found that 
intracellular chloride accumulation shifts GABAAR-mediated currents from hyperpolarizing to 
depolarizing and dampens the efficacy of GABA-mediated inhibition in the adult Ts65Dn mice 73. 
Accordingly, MEA recordings of network activity in hippocampal cultures form Ts65Dn mice showed the 
presence of a population of neurons in which GABAergic signaling is depolarizing and therefore in which 
GABAAR activation favors excitation. Although intracellular chloride imaging showed a decrease in 
chloride levels in most of Ts65Dn neurons, only 13% of the electrodes recording from Ts65Dn networks 
showed an increase in mean firing rate after GABA administration. However, it should be noted that 
GABA administration activates both GABAA channels and GABAB GPCR. In addition, since subunit 2 of 
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GIRK channel is triplicated in DS and DS mouse models, GABAB/GIRK currents result increased in 
primary hippocampal neurons, enhancing GIRK-mediated shunting inhibition 72 and mitigating the 
increased neuronal excitability due to increased [Cl-]i.  
 
Optimal neural network activity and brain functions critically depend on the correct balance between 
excitatory and inhibitory synaptic inputs. In fact, precise control of [Cl-]i is necessary to ensure the 
efficacy of synaptic inhibition trough chloride-permeable GABAARs. In mature neurons,  low [Cl-]i  
determines an inward (hyperpolarizing) flow of negatively charged chloride ions through GABAARs 215. 
However, relatively small changes in neuronal [Cl-]i are sufficient to switch the polarity of GABAergic 
responses from hyperpolarizing to depolarizing 215,216. Therefore, [Cl-]i must be tightly controlled in 
neurons to ensure appropriate GABAergic inhibition and avoid catastrophic consequences on 
excitatory/inhibitory balance and neural network activity. Regulation of neuronal [Cl-]i is mainly 
controlled by the opposite action of two major cation/chloride cotransporters: the Cl− importer NKCC1 
and exporter KCC2 217,218. During development, changes in the levels of the two cotransporters trigger the 
developmental GABAergic switch from depolarizing to hyperpolarizing 55. Interestingly, alteration of 
neuronal chloride homeostasis due to changes in the expression or the transport activity of NKCC1 or 
KCC2 may also occur later in life and seems to be a common feature of a wide range of 
neurodevelopmental and neurological disorders 216 including: chronic pain 66, brain trauma 67-69, autism 
spectrum disorder 70,71, Rett syndrome 74,75, Parkinson disease 219, Fragile X syndrome 71,76, Huntington 
disease 77, Tuberous sclerosis 78, 22q11.2 microdeletion syndrome 79, maternal immune activation 80 and 
some form of epilepsy 81-83,220,221.  
In our experiments, NKCC1 upregulation caused an intracellular chloride accumulation leading to a 
depolarizing effect of GABAergic transmission. Overexpression of both miR101-3p and miR497a-5p, 
restored the hyperpolarizing action of GABAergic transmission, through the downregulation of NKCC1 
and the reestablishment of physiological chloride concentration in trisomic neurons. 
Given its importance in brain physiology, many studies have addressed the mechanisms controlling 
KCC2 expression and activity. For instance, KCC2 activity is known to be regulated by post-translational 
modifications such as phosphorylation of key residues 222. Serine 940 is one of the most important PKC 
phosphorylation sites on KCC2 C-terminal domain, and its phosphorylation status influences the cell 
surface stability and activity of the cotransporter 59. Moreover, KCC2 functions are also regulated in an 
activity-dependent manner. Indeed, sustained neuronal stimulation or interictal-like activity can reduce 
KCC2 membrane levels through BDNF-dependent activation of the TrkB receptor or calpain protease 
cleavage 223,224. Interestingly, KCC2 expression and surface targeting have been shown to be regulated by 
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the HSA21 gene APP. A first report showed that APP knockout in mice resulted in significant reductions 
in both total and membrane KCC2 levels, leading to a depolarizing shift in the GABA reversal potential. 
APP regulation of KCC2 was shown to be mediated by direct protein-protein interaction by acting on 
KCC2 phosphorylation and ubiquitination 64. Conversely, a second report showed that overexpression of 
human APP in rat cortical neurons decreased KCC2 expression and depolarized the GABA reversal 
potential 225. While both studies did not found any difference in NKCC1 expression and regardless of the 
contradictory results, it is interesting to notice that a DS-triplicated protein may be involved in the 
regulation of chloride homeostasis.  
While these studies have investigated how APP protein modulated KCC2 levels, in our work we have 
highlighted that also APP mRNA could play a role in the regulation of chloride homeostasis. In our 
hypothesis, the ability of APP to regulate NKCC1 levels could be mediated by a variation in microRNA 
levels. According to recent studies, microRNAs degradation can take place after their loading into AGO 
protein when the pairing with target RNA induces the destabilization of the bound microRNA, a process 
known as target RNA-directed miRNA degradation (TDMD). In most of the cases, TDMD is triggered by 
an elevated degree of complementarity between the target RNA and the microRNA, especially at the 
3'end of the microRNA. However other factors may play a role in determining if the mRNA-miRNA 
interaction will result in gene silencing or in TDMD, such as relative mRNA-miRNA abundances and 
interestingly, in some cases, high expression levels of the target may compensate for a low degree of 
complementarity. Moreover, the requirements for TDMD occurrence may differ for different microRNAs 
and in different cellular systems 226. For instance, TDMD has been shown to be particularly effective in 
primary neurons 227. For this reasons, we hypothesize that being overexpressed in Ts65Dn neurons, APP 
mRNA could, at least in part, mediate  the degradation of microR101-3p and miR497a-5p, even though 
their complementarity does not extend to the 3' end of the microRNAs.  
 
Intracellular chloride accumulation has been observed in several pathological conditions, causing an 
excitatory-inhibitory imbalance and disrupting neuronal communication.  
Several neurodevelopmental disorders are associated with increased [Cl-]i, due to the dysregulation of one 
or both the chloride cotransporters. Indeed, enhanced NKCC1 and reduced KCC2 levels characterize 
different epilepsy syndromes, as shown in animal models and human tissue studies 228-231. Animal models 
of others pathologies show dysregulation of KCC2 alone or of both NKCC1 and KCC2 66,71,74,75,77,81,232. 
Schizophrenia pathology has been associated with loss-of-function mutations of KCC2 and gain-of-
function mutation of NKCC1 genes, implying a role for altered chloride levels in the pathogenesis of the 
disease 233,234. On the other hand, in iPSC-derived neurons from Rett syndrome patients chloride reversal 
potential was depolarized due to only KCC2 reduction 75. Accordingly, analysis of cerebrospinal fluid 
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from Rett syndrome patients found a decrease in KCC2 levels, while NKCC1 levels were not altered 235. 
Interestingly, in DS, only the expression of NKCC1 was found enhanced, while no changes were found in 
KCC2, in both human and mouse brain samples 114. 
According to the amplified developmental instability hypothesis, in addition to overexpression of 
triplicated genes in trisomic cells, a secondary contribution to the pathology will come from global 
dysregulation of gene expression. A recently reported example concerns the endocannabinoid system. The 
expression of the most abundant cannabinoid receptor in the brain (CB1R) was found increased in the 
excitatory terminals of the hippocampus in Ts65Dn mice. Nevertheless, CB1R mRNA levels did not 
differ between WT and Ts65Dn mice 236. Similarly, we found that NKCC1 cotransporter was upregulated 
in Ts65Dn brains and primary neuronal cultures while its mRNA levels were unchanged. Interestingly, 
we also found that NKCC1 protein degradation was actually slightly faster in Ts65Dn neurons. The 
increase in degradation speed is limited and probably does not lead to any physiological consequence due 
to slow NKCC1 turn-over, however, this evidence indicates that decreased protein turnover cannot 
account for the observed increase in the transporter expression.  
On the other hand, we found that in Ts65Dn neurons post-transcriptional repression exerted on the 3'UTR 
of NKCC1 was reduced and may therefore contribute to NKCC1 protein upregulation in DS.  
Among the regulators binding to 3’UTRs of genes, microRNAs, control gene expression at the post-
transcriptional level by mainly (although not exclusively) interacting with the 3’UTRs of target genes 
trough the RISC complex. Therefore, we reasoned that if NKCC1 levels are regulated by microRNA, 
interfering with their repression activity would affect NKCC1 expression. In fact, we found that inhibiting 
microRNA activity by knockdown of Tnrc6C, a fundamental component the RISC complex 135, increased 
NKCC1 protein expression.  
MicroRNAs play an essential role during development, modifying protein expression with high spatial 
and temporal precision 140,237. Indeed, many developmental disorders are associated with microRNA 
dysregulation. For instance, FMRP protein (whose mutation causes Fragile X syndrome) regulates some 
components of the microRNA pathway and its mutation is associated with altered microRNA profiling 
157,172,238. Additionally, a single nucleotide polymorphism (SNP) within the primary transcript of miR137 
that modifies the levels of this microRNA, has been associated with schizophrenia risk 150,169. 
Furthermore, microRNAs targeting ion channels can influence neuronal excitability, being involved in all 
stages of epileptogenesis 156,239,240. In Down syndrome, in addition to microRNAs encoded on 
chromosome 21, many others have been reported to be dysregulated in different tissues 163,164,166,167,241. 
Our RT-qPCR screening of microRNAs in Ts65Dn hippocampi and primary neuronal cultures as well as 
in human DS hippocampi, found two downregulated microRNAs predicted to target NKCC1 3’UTR: 
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miR497a-5p and miR101-3p. Interestingly, both microRNAs had been previously found to target 
NKCC1. miR101 was shown to regulate NKCC1 (together with other targets) during early development, 
leading to the establishment of balanced network excitability later in life. Indeed, transient inhibition of 
miR101 during development delayed the GABAergic developmental switch and resulted in increased 
neuronal excitability in adult mice 242. miR497a-5p is part of a large family of microRNAs sharing the 
same seed sequence and mRNA targets: miR15a-5p, miR15b-5p, miR16-5p, miR195-5p, miR322-5p. 
Among these, miR15a-5p was shown to reduce NKCC1 translation during mouse inner ear development 
243. Interestingly, a large genome-wide screening experiment by high-throughput sequencing of RNA 
isolated by crosslinking immunoprecipitation (HITS-CLIP) showed Ago2-mediated interaction of both 
miR101-3p and components of the miR497a-5p family to NKCC1 mRNA in mouse brain 244. Notably, 
both miR497a-5p and miR101-3p had already been found dysregulated in DS models 163,165,245. 
By mutation, overexpression and downregulation studies, we demonstrated that both miR497a-5p and 
miR101-3p act as NKCC1 post-transcriptional repressors in neuronal cultures. Therefore, decreased 
levels of miR497a-5p and miR101-3p likely drive NKCC1 upregulation in trisomic neurons.  
From a more functional point of view, we have found that re-expression of both microRNAs restores 
physiological chloride levels and GABAergic inhibitory signaling in trisomic neurons, indicating these 
small RNAs as possible tools for therapeutic intervention. 
Clearly, other mechanisms are involved in NKCC1 regulation and compensatory mechanism may 
counteract the effect exerted by microRNAs on NKCC1-3'UTR. This could explain why, in WT neurons, 
NKCC1 protein does not increase to Ts65Dn levels after inhibition of miRISC functionality or upon 
microRNA antagonization. 
Interestingly, we found that the triplicated gene APP shares with NKCC1 predicted binding sites for both 
miR497a-5p and miR101-3p. Therefore, restoring the expression of these microRNAs has the potential to 
normalize both APP and NKCC1 levels. Accordingly, we showed that overexpression of miR497a-5p and 
miR101-3p mimics downregulated APP in both WT and Ts65Dn neurons. This further increases 
microRNAs overexpression potential as a therapeutic option to treat cognitive impairment, acting 
simultaneously by restoring chloride homeostasis and reducing APP levels to delay early-onset 
Alzheimer's disease observed in people with Down syndrome.  
The observation that triplicated genes can impact on the entire transcriptome not only through the 
expression of upregulated transcription factors and regulatory proteins but also in a coding-independent 
manner through the upregulation of mRNA transcripts, may have a more mechanistic implication 
regarding how chromosome 21 triplication may affect in trans the expression of other genes. According 
to the “competitive endogenous RNA” (ceRNA) hypothesis, mRNAs bearing seed-binding sequences for 
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the same microRNAs influence each other by competing for a limited pool of these microRNAs. 
Therefore, changes in the levels of one of the predicted microRNA targets can relieve or potentiate 
microRNA repression on competitive targets 201,202. For example, many ceRNAs couples are expressed 
with stage-specificity and can act sequentially or synergistically to tune and coordinate specific functions 
during brain development. Moreover, their competition for microRNAs can mediate the crosstalk between 
different signaling pathways 246. Competition can take place between protein-coding or non-coding RNAs 
such as pseudogenes and circular RNAs (circRNAs). For instance, PTENP1 is a pseudogene sharing 
microRNA-binding elements with the tumor suppressor gene PTEN (phosphatase and tensin homolog). 
Overexpression of PTENP1-3’UTR leads to growth inhibition and increased levels of PTEN by 
competing for the same microRNAs. On the other hand, copy number losses at the PTENP1 locus have 
been identified in sporadic colon cancer, suggesting a tumor suppression function for PTENP1 247.  
Additionally, also circRNAs can efficiently act as microRNA sponges and have been involved in brain 
pathologies. For instance, the circRNA antisense to the cerebellar degeneration-related protein 1 transcript 
(CDR1as) harbors more than 70 microRNA-binding elements for miR7, and has therefore been named 
ciRS-7. The main role of ciRs-7 is to bind miR7 and its ectopic expression phenocopied miR7 
knockdown, causing morphological midbrain deficits 248,249. Interestingly, ciRS-7 is downregulated in the 
hippocampus and cortex of Alzheimer’s disease patients. ciRS-7 downregulation has been associated with 
a de-repression of miR7 function and the downregulation of its known downstream target ubiquitin 
conjugating enzyme E2A (UBE2A), involved in ubiquitin-mediated degradation of amyloid peptides 250. 
miR7 can also target α-synuclein mRNA, a protein involved in Parkinson’s disease pathogenesis 251. 
Therefore, ciRS-7 could possibly be involved in a ceRNA network contributing to the progression of 
neurodegenerative diseases 248,252.  
Moreover, Valluy et al. found that a particular transcript of UBE3A gene (Ube3a1), whose duplication is 
frequently observed in autism, can possibly act as a ceRNA during development to regulate dendrite 
growth and prevent premature spine maturation253. Therefore, the ceRNA mechanism possibly plays a 
role also in the onset of neurodevelopmental disorders. 
In our context, due to the presence of a supernumerary copy of the APP gene, a higher amount of 
miR497a-5p and/or miR101-3p may bind to APP 3'UTR, leading to a lack of repression exerted on other 
microRNA targets, including NKCC1. Therefore, we hypothesized that variations in the levels of free 
miR497a-5p and miR101-3p (due to APP triplication) could represent the missing link between the 
trisomy of chromosome 21 and NKCC1 upregulation. In fact, our preliminary data, obtained through the 
downregulation of APP with a specific shRNA, indicate that knockdown of APP downregulates NKCC1 
protein in Ts65Dn neurons, establishing a direct connection between trisomy and GABAergic 
dysfunctions. However, further experiments are needed to establish whether the decrease in miR497a-5p 
  69 
and miR101-3p occurs as a consequence of their binding to APP 3'UTR (possibly through the TDMD 
process) or if the reduction of miRNA levels and APP competition for binding are independent 
phenomena. Interestingly, APP has already been shown to play a role in cortical development by 
suppressing the levels of a specific microRNA (miR574-5p). In this case, the authors hypothesize that 
APP protein is acting through transcriptional inhibition, however, the specific molecular mechanism 
involved in the suppression of miR574-5p is not fully clarified in the study 254.       
 In conclusion, we identified a lack of microRNA-mediated inhibition of translation as the cause of 
NKCC1 upregulation, which leads to intracellular chloride accumulation in the Ts65Dn model of DS. 
Defective translational repression derives from the downregulation of miR497a-5p and miR101-3p in 
trisomic neurons. Interestingly, four triplicated genes, APP, Dyrk1A, RUNX1 and BACE2, are predicted 
targets of these two microRNAs. This implies that, as predicted by competitive endogenous RNA 
hypothesis, the 3'UTR of those genes probably act in trans, by binding the shared microRNAs, resulting 
in the de-repression of NKCC1. Accordingly, our preliminary results obtained with APP shRNA show 
that APP downregulation causes a decrease in NKCC1 levels. 
Using molecular biology and biochemical approaches as well as MEA recordings, we have demonstrated 
that overexpression of miR497a-5p and miR101-3p can reduce NKCC1 levels, restoring physiological 
[Cl-]i and the hyperpolarizing action of endogenous GABAergic transmission. Therefore, this approach 
has the potential to rescue the cognitive deficits characterizing Ts65Dn model. We decided to perform 
these experiments using tranfection of miRNA mimics as a first approach, due to their immediate 
availability. However, this approach carries some limitations as it only allows a short-term evaluation of 
miRNA activity and the percentage of transfected neurons can be low compared to neuronal cultures 
transduced with viral vectors. For this reason, we are performing validation experiments using viral 
vectors to overexpress microRNAs in order to perform measurements with higher targeting efficacy and 
on a longer time-scale and to better evaluate the consequences of miR497a-5p and miR101-3p long-term 
overexpression. In addition, to improve data reliability, we will perform further experiments trying to 
overcome the limitations affecting the study. For instance, even though all the experiment were carried 
out using a control microRNA, bearing a scramble sequence, we will repeat the key experiments using a 
non-related microRNA (which is not predicted to target any of the proteins involved in the study) as an 
additional negative control.   
Moreover, to better elucidate the molecular mechanisms linking APP to NKCC1 we will separately 
overexpress APP coding sequence and APP-3' UTR to investigate whether the effect on NKCC1 is 
mediated by 3’UTR RNA.  
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A further step will require understanding whether the ceRNA action exerted by APP is associated to 
TDMD, causing the observed decrease in miRNAs levels, or the two phenomena are independent. To 
address this point, we will check variations in miR497a-5p and miR101-3p levels in WT and trisomic 
neurons after APP knock-down and APP-3’UTR overexpression  
Eventually, to test the ability of microRNAs overexpression to rescue cognitive impairment and their 
value as a target for future therapy, we will perform stereotaxic injection in the hippocampus of WT and 
Ts65Dn mice and then perform behavioral tests to assess mice memory and learning performances. 
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